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ABSTRACT 
The selection of the best response variables in a clinical trial is often not straightforward; 
the primary endpoint of a trial should be clinically relevant, directly related to the primary 
objective of the trial, and with favorable efficiency to detect the treatment benefit with a 
reasonable sample size and duration of the trial. With the recent success in the management 
of heart failure, the mortality rate has dropped significantly compared to two decades ago, 
and patients with heart failure have high rates of hospitalization and morbid complications 
along with multiple symptoms and severe limitations in daily activities. Although mortality 
still remains important as a measure of the clinically relevant benefit and the safety of the 
intervention, with the low event rate of mortality, it requires large and longer clinical trials 
to detect treatment benefit of new intervention using mortality as the sole primary endpoint. 
Thus most heart failure trials use the combined endpoint of death and a second efficacy 
outcome, such as hospitalizations. This is often analyzed with time-to-first-event survival 
analysis which ignores possible subsequent hospitalization events and treating the death 
and first hospitalization equally in the importance and hierarchy of clinical relevance. 
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Accounting for the recurrent events or subsequent death after the hospitalization(s) 
provides more detailed information on the disease-control process and treatment benefit.  
In this dissertation we propose a hierarchical endpoint with death in the higher priority and 
number of hospitalization events in the lower priority as primary endpoint to assess 
experimental treatment benefit versus a control using a non-parametric generalized Gehan-
Wilcoxon test. In addition to the hierarchical endpoint, we also evaluated assessment of 
experimental treatment benefit on recurrent events with a multi-state model using extended 
stratified Cox model, considering the multi-states in which patients might transition during 
the study. We compared the false positive rate and power of the above mentioned methods 
with the composite endpoint approach and recurrent event endpoint approach analyzed 
using Andersen-Gill, WLW, and PWP models in simulation studies. Finally we applied all 
evaluated procedures to the Digitalis Investigation Group (DIG) trial.  
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Chapter 1 Introduction 
1.1 Overview 
Patients with heart failure have high rates of mortality, hospitalization and morbid 
complications, along with multiple symptoms, and severe limitations in daily activities, 
thus resulting in a poor quality of life.(1) In order to evaluate new treatments for heart 
failure, the randomized clinical trials are the standard scientific method to assess the 
efficacy and safety of any new medications or devices. However, selection of the 
appropriate efficacy endpoint for heart failure clinical trial is not straightforward and may 
be subjectively chosen varied by different investigators. In the published heart failure 
clinical trials, a wide range of endpoints have been chosen to assess efficacy including all-
cause mortality, cause-specific mortality, hospitalization rate, composite endpoints of all-
cause mortality or time to first heart failure hospitalization, and other soft endpoints such 
as function status and left ventricular function, and others.(1-3) However to select the best 
endpoint and appropriate statistical method for analyzing the endpoint for HF clinical trial 
also depends on the mechanism of action of the test drug and regulatory requirement on 
the indication the drug will be intended to use. The decision on choosing which type of 
efficacy endpoint will also have a great impact on study design, in particular the size of 
trial and the duration of study.  
In the following section, we review the endpoints we will focus on assessment in 
our research work.  
1.2 Endpoints for HF Clinical Trials  
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1.2.1 Mortality  
With the better treatment options for heart failure patients, such as angiotension-
converting enzyme (ACE) inhibitors, beta-blockers, mineralocorticoid receptor antagonists, 
and devices (implanted cardioverter defibrillators and cardiac resynchronization therapy) 
have completely changed the prognosis for patients with heart failure recently.(4) The 
improvement in medical care of heart failure converted this relatively short-term and 
quickly fatal condition to a chronic disease characterized by recurrent non-fatal events 
(hospitalizations) and other comorbid complications. The change in the disease progression 
and disease management in heart failure makes the all-cause mortality no longer an 
attractive endpoint for HF clinical trials. Because the mortality rate in HF has dropped so 
dramatically, in order to achieve statistical power, it usually requires a large sample size 
and longer duration of follow-up. Of course, this endpoint can still be appealing to the 
sponsors and regulatory agency if the test drug or device is targeting at the high-risk HF 
patient population where the mortality rate remains high, because the mortality is the most 
unbiased endpoint and easy to measure, and clearly represents an important and clinical 
meaningful event. The common way of analyzing mortality data is based on the standard 
Kaplan Meier estimator or Cox proportional hazards regression model. 
1.2.2 Hospitalization 
As discussed previously, with better treatment and patient management for HF 
patients, used to be relatively short-term and fatal disease becomes chronic disease. 
Patients with heart failure have an impaired quality of life and increased morbidity usually 
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requiring frequent hospitalization. Thus, hospitalization is a frequent, usually important 
experience for the patient, is an integral part of the morbidity of the disease, predicts a high 
mortality and is a major contributor to health-care costs. Based on the literature, heart 
failure is a leading cause of hospital admission and readmission for Medicare 
beneficiaries.(5) The hospitalizations undergone by patients with heart failure are 
frequently assumed by researchers to be a surrogate for worsening disease, for health 
related quality of life, and others.(2) It has been reported that heart failure is the leading 
cause of hospitalization among adults >65 years of age in the United States. Annually, >1 
million patients are hospitalized with a primary diagnosis of heart failure, accounting for a 
total Medicare expenditure exceeding $17 billion.(5)  This has made hospitalization a 
popular outcome for research into heart failure trials. For all the reasons, it is important to 
consider hospitalization as part of outcome measure in HF clinical trials. Most 
hospitalizations in patients with HF are for conditions other than worsening HF. The effect 
of treatment on these non-fatal, recurrent events is important to quantify, but there is 
controversy as to which statistical methods to analysis are the most appropriate. However, 
there is one potential criticism of hospitalization as an endpoint in international clinical 
trials is potential country-to-country variations due to medical practice difference. In the 
literature, hospitalization data can be analyzed by the mean number of hospitalizations and 
the mean number of days in hospital or time to first hospitalization. Due to the skewed 
distribution of number of hospitalization and number of days in hospital, normality 
assumption is violated and usually non-parametric test was used this type of data. Time to 
first hospitalization is analyzed by survival analysis. However, in the recent years, more 
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and more researchers start to assess multiple repeat hospitalization data as recurrent event 
data. 
1.2.3 Composite Endpoint 
The composite endpoint has been adopted in the clinical trials frequently by 
combining several clinical endpoints into a single endpoint and each endpoint is considered 
as a component of the composite endpoint. (3, 6) Instead of separate analysis of each 
endpoint, there will be only one single analysis, thus there is no multiplicity adjustment 
needed in this case. The widely used composite endpoint in HF trials is death or first 
hospitalization and usually analyzed with traditional time to first event analysis. The 
primary rationale for adopting this type of composite endpoint in HF clinical trial is that 
composite endpoint may potentially reduce the required sample size and the duration of 
trials as the mortality rate has declined dramatically with better medical treatment for HF 
patients. Event rates are higher when including the occurrence of hospitalization event in 
a composite endpoint, which can lead to reduced sample size for a given level of power 
and trial duration. Furthermore, the adoption of composite endpoint may avoid the need to 
adjust for multiple comparisons by considering only a single event. However, the use of 
composite endpoint in HF trials is not without controversies, and there are several 
disadvantages of composite endpoint. The most frequently mentioned disadvantage is that 
of heterogeneity. There are two type of heterogeneity. First, the treatment effect may be 
different across the two components and second, the clinical importance of component 
endpoints may be very different. When the component endpoints from a composite 
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endpoint are of different clinical importance, the interpretation of the treatment effect from 
a composite endpoint analysis can be misleading if the overall positive result driven by a 
treatment effect on a less important endpoint. Moreover, if the magnitude of the treatment 
effect on components are very different, the interpretation is problematic as well. From a 
statistical point of view, the inclusion of a component with little or no treatment effect can 
dilute the evidence of a treatment effect and hence may lead to reduced power when testing 
the efficacy of treatment. Of course, there is a large drawback using time to first event type 
of composite endpoint is that it ignores a vast amount of recurrent hospitalization or 
subsequent death in HF trials and treat death and hospitalization events equally in terms of 
clinical meaningfulness of the endpoint.(4) Clinically, those ignored hospitalization events 
should not be underestimated, because such hospitalizations are not only distressing for 
patients and their families, but they are also predictive for accelerated disease progression 
(indicated by increased risk of re-hospitalization and death) and the major driver of the 
economic burden of heart failure. This composite endpoint is usually analyzed by Kaplan 
Meier method or proportional hazards model. 
1.2.4 Recurrent Event Endpoint 
In recognition of drawback of ignoring the repeat hospitalization events in the 
composite endpoint analysis, it is important to quantify the treatment benefit on these 
recurrent, non-fatal events because the true benefit of treatment should be determined by 
its effect on all events and not just first events as did in the composite endpoint. 
Understanding the subsequent hospitalization events will provide detailed information on 
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the disease control process and worth modeling to get a more precise understanding of 
treatment benefits. However, there is an obvious problem with recurrent event data using 
any standard survival analysis, and that is the recurrent events are not independent. One 
can only have a second hospitalization event after having a first event, and one can 
experience third one after a second, and so on (and must be alive to do so). Because of the 
dependence between events and other characteristics of recurrent events in HF patients, the 
standard statistical approach might not be appropriate for this type of events as it assume 
events as independent observations and assume proportionality of hazard.(4) We will 
describe some special statistical methods in more details for analyzing this type of data in 
Chapter 2. Among them, we will evaluate the multi-state model which allows a flexible 
modelling strategy that incorporates important features in the analysis of hospitalization 
and death, and at the same time extends relevant characteristics of models proposed by 
Andersen and Gill et al. (7), Wei et al (8) , and Prentice et al (9). 
1.2.5 Hierarchical Composite Endpoints 
Understanding the limitation of using composite endpoints (ie, time to death or first 
hospitalization) which treats both events equally in importance of the clinically 
meaningfulness and ignores the subsequent events, and the assumptions for recurrent event 
analysis model might not be easily met in HF clinical trial, we adapted an approach 
proposed by Finkelstein and Schoenfeld (10) to combine death and hospitalization events 
in a single statistical test by treating two or more components in hierarchical order. It is a 
modification of the generalized Wilcoxon test. We adapted this approach to come up with 
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a different combination of mortality and hospitalization events as the combined endpoint 
in HF trials. Generally, each patient in the active group is compared with each patient in 
the placebo or control group in a pairwise manner. The hierarchy of the endpoint was 
formed as such, the time to death will be compared in the first priority if applicable, 
followed with secondary priority endpoint such as time to first hospitalization, or number 
of hospitalization, or total days in the hospital, etc. This approach can be extended to three 
or more components with pre-specified hierarchical order, for example, first order with 
death, second order with total number of hospitalization, and third order with time to first 
hospitalization. With this approach, all the relevant death and hospitalization can be 
integrated to form an informative test for comparing treatment group with control group in 
HF trials. This new type of endpoint using both mortality information and all relevant 
hospitalization data while keeping mortality as the higher importance in terms of clinical 
relevance and clinical meaningfulness provides more complete and precise treatment effect 
compared to composite endpoints treating both mortality event and hospitalization events 
equally important as the event for the analysis. 
1.3 Objectives of the research 
Although composite endpoint of time to death or first hospitalization has been 
widely adopted endpoint in the HF clinical trials, the one of the limitation of this approach 
is that the treatment effect might be fully driven by the effect from hospitalization endpoint 
even if the effect in mortality is small or negative, which makes difficult to interpret the 
clinical outcome of the trial. Our specific objective is to evaluate the proposed hierarchical 
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endpoints as well as other methods in a setting where the primary objective of the HF trial 
is to evaluate treatment efficacy under two type of designs: with the fixed duration follow-
up for all the patients and with variable follow-up durations for different patients. The fixed 
duration design is pretty common in Phase 2 trials, where sponsors want to have a quick 
proof of concept studies in a short period of time. As the event rate of mortality will be low 
due to the short follow-up, usually this type of Phase 2 studies will not have sufficient 
power to detect the treatment benefit in mortality, thus the investigator will make go-no-
go decision based on other endpoints, such as hospitalization rate, or combine mortality 
with time to first hospitalization as an endpoint. We will evaluate a couple of endpoints 
using the pre-specified hierarchical order using death and hospitalization information. The 
results will be compared to those using single endpoint, composite endpoint, and recurrent 
event endpoint. We will extend our research to more dynamic design where each patient 
has different duration of follow-up, in which it add the complexity of comparing the 
component in the hierarchical endpoint with lower priority, as it needs to compare them in 
the shortest common duration of follow-up duration between each pair. We will discuss 
the algorithm in the Chapter 5. Our research work on assessing the utility of hierarchical 
endpoint approach in HF in the fixed follow-up design is a new contribution to the area of 
HF clinical trial research, and the extension to the variable follow-up design with dynamic 
pair-wise comparison provides more flexibility for analyze hierarchical endpoint data in 
general design. 
1.4 Outline of the work 
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This work is motivated by the need to understand the implication of using time to 
first event endpoint in HF clinical trials and explore the appropriate statistical methods to 
evaluate the repeated hospitalization and cardiovascular death data and propose the 
alternative statistical methods for efficiently evaluating efficacy endpoints in HF clinical 
trials.  
We will review the statistical methods in analyzing mortality and hospitalization 
outcome as different type of endpoints in HF clinical trials in Chapter 2. Those methods 
include Kaplan Meier estimator and Cox proportional hazards model for time to first event 
endpoints; recurrent event models including Andersen-Gill model(7), Wei, Lin, and 
Weisser (WLW) model(8), PWP model(9), Poisson and negative binomial model for event 
rate data. In our research, we have strong interest to evaluate two methods which have not 
be commonly used in the clinical trials, multi-model to evaluate recurrent event endpoint 
and hierarchical endpoints using generalized Gehan-Wilcoxon test. For hierarchical 
endpoint, we adapted the method proposed by Feinstein and Schonfeld(10) and Buyse(11) 
to combine multiple outcomes into a single non-parametric test using generalized pairwise 
comparison with pre-specified hierarchical order for the different outcomes. For the multi-
state model for recurrent model, we extended the stratified Cox model to account for the 
transition state and the nature of the event. In Chapter 3, we will compare the performance 
of each method on their corresponding endpoints in the simulation studies. Because the 
hierarchical pairwise comparison for multiple components of endpoints with death as the 
higher priority need to compare the lower priority variable in the common follow-up time 
between the pair, we will simulate the study with fixed length of follow-up for all the 
10 
 
 
 
 
subjects at first for the simplicity. In Chapter 4, we will apply the evaluation of each 
approach in the real life data. In Chapter 5, we will extend the simulation studies for the 
hierarchical endpoints using dynamic comparison by comparing the secondary hierarchy 
endpoints in the shortest common follow-up duration where the study did not have fixed 
follow-up for all the patients. Chapter 6, we reanalyzed the DIG trial data in the long-term 
follow-up data where patients have different follow-up duration. Chapter 7 provide a 
conclusion of the work and discussion of future work.  
  
11 
 
 
 
 
Chapter 2  Statistical Methods in Analyzing HF Endpoints 
2.1  Method for Analyzing Time to Single Event Endpoint 
In heart failure clinical trials, mortality, time to first hospitalization, and composite 
endpoint (time to death or first hospitalization) will be analyzed using standard survival 
analysis (Kaplan-Meier estimator and Cox proportional hazards model). Survival analysis 
is a class of statistical methods for analyzing time-to-event outcome. Let T be a random 
variable indicating survival time, such as time to an event of interest or the end of follow-
up. Those subjects who have not experienced the event of interest are called censored 
observations. It is assumed that censored observations have the same distribution of time 
until the event as observations that experience the event. Thus, survival time is the length 
of time from a participant’s entry into the study until the event of interest or censoring.  
The Kaplan-Meier (KM) estimator is a nonparametric maximum likelihood 
estimator of survival function. The value of decreases in estimated survival function at a 
given survival time depends on the number of censored individuals preceding the observed 
event, as well as the number of events observed at each event time. If no censoring occurs, 
the empirical survival function drops by one divided by the sample size (probability mass 
= 1/n) at each survival time. With censoring, no subject fails at a point that corresponds to 
a censored subject; thus, survival function does not change and the probability mass is 
equal to zero at the censoring point. Next, the probability mass is recalculated for all larger 
durations for both uncensored and censored individuals. The KM estimate is calculated by 
subtracting the adjusted probability mass at the current survival time from the KM estimate 
12 
 
 
 
 
at the previous survival time. 
The hazard function, h(t), is the incremental change in F(t) over an infinitesimally 
short time interval, conditional on surviving until the time of interest: 
ℎ(𝑡) = lim
∆→0
Pr(𝑡 ≤ 𝑇 < 𝑡 + ∆𝑡|𝑡 ≤ 𝑇)
∆𝑡
=
𝑓(𝑡)
𝑆(𝑡)
 
 
The hazard function may be more informative for the underlying mechanism of failure than 
survival. It can be interpreted as the instantaneous incidence rate of an event at time t in 
subjects who have survived until time t. 
The cumulative hazard function of time t, H(t), is the integral of the hazard function, 
corresponding to area under the hazard function over the time interval [0,t]: 
𝐻(𝑡) =  ∫ ℎ(𝑢)𝑑𝑢 =  − 𝑙𝑛  (𝑆[𝑡])
𝑡
0
 
2.2 Cox Proportional Hazard Model 
The Cox proportional hazards model, named for D. R. Cox, has become the most 
used method, which takes into account the effect of censored observations, is a powerful 
survival analysis technique used to determine the relationship between an explanatory 
variable and a specific outcome. (12) Individuals are followed through time, typically from 
a baseline time point until their respective event of interest or until censoring. The notation 
used in the Cox proportional hazards model is as follows. The model can be stated in terms 
of hazard function at time t as: 
ℎ(𝑡) = 𝜆0(𝑡)exp (𝑥(𝑡)𝛽) 
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where 𝑥 is a 1 x p vector of explanatory variables, 𝜆0(𝑡) is an unspecified and arbitrary 
baseline hazard function when ?̃? = 0, and 𝛽 is a p x 1 vector of regression parameters. 
The survival function is derived as follows: 
∫ ℎ(𝑢)
𝑡
0
𝑑𝑢 = ∫ 𝜆0(𝑢)𝑑𝑢 ∗
𝑡
0
exp (𝑥(𝑡)𝛽) 
𝐻(𝑡) = ∫ 𝜆0(𝑢)𝑑𝑢 ∗ exp (𝑥(𝑡)𝛽)
𝑡
0
 
𝑒𝑥𝑝[−𝐻(𝑡)] = 𝑒𝑥𝑝 [−∫ 𝜆0(𝑢)𝑑𝑢 ∗ exp (𝑥(𝑡)𝛽)
𝑡
0
] 
𝑆(𝑡) = [𝑒𝑥𝑝 (−∫ 𝜆0(𝑢)𝑑𝑢
𝑡
0
)]
exp (𝑥(𝑡)𝛽)
 
𝑺(𝒕) = [𝑺𝟎(𝒕)]
𝐞𝐱𝐩 (𝒙(𝒕)𝜷) 
where 𝑆0(𝑡) = 𝑒𝑥𝑝 [−∫ 𝜆0(𝑢)𝑑𝑢
𝑡
0
] is the baseline survival function. The Cox model is 
also called a semi-parametric model, since it allows an unspecified form for the underlying 
survival or hazard functions. 
Cox proposed the method of partial likelihood to estimate parameters under the 
assumption of PH, based on rank ordering of the observed event (or failure). The partial 
likelihood for parameter 𝛽 is defined as: 
∏ 𝑙𝑗
𝐽
𝑗=1 = ∏
exp (𝑥(𝑡)𝛽)
∑ exp (𝑥(𝑡)𝛽)𝑖∈ 𝑅(𝑡𝑗)
𝐽
𝑗=1 , 
where 𝑙𝑗 is the likelihood that the ith subject who fails at the jth event time would be the 
specific subject of all subjects at risk at the time tj to fail. R(tj) is the set of all individuals 
who are still surviving at a time prior to tj, (assuming there are no ties). The likelihood 
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function is more complex when there are tied event times. The Maximum Likelihood (ML) 
procedure is used to estimate the coefficient vector, 𝛽. 
Hazard ratio is always used to summarize survival data based on the maximum 
partial likelihood estimate of β. For example, for the two-sample situation with a single 
grouping variable (X) coded as 0 or 1, HR for the two groups is determined by the following: 
𝐇𝐑(𝐗𝐱=𝟏: 𝐗𝐱=𝟎) =
𝛌𝟎(𝐭)𝐞
(?̂?𝐗𝐱=𝟏)
𝛌𝟎(𝐭)𝐞(?̂?𝐗𝐱=𝟎)
= 𝐞?̂? 
The (1 – α) 100% confidence interval for the hazard ratio is: 
exp (?̂?) ± 𝑍1−𝛼 2⁄ 𝑠𝑒(?̂?) 
The Cox PH regression model does not assume a distribution of time to event, but 
does assume that hazard functions for any two different subjects or groups are proportional 
over time. This is called PH or proportionality. Under the PH assumption, the hazard ratio 
for two groups in a two-sample study with a single binary variable (0, 1) is equal to the 
exponent of the coefficient, which implies that the effect of group (or treatment) does not 
change over follow-up. It is very important to verify the assumption of proportionality. If 
this assumption is violated, the Cox model may be invalid and other summary measures or 
modeling procedures may be required. 
2.3 Stratified Cox PH Models 
An extension of the Cox PH model allows for multiple strata. This model assumes 
that the strata divide the subjects in disjoint groups, each of which has a distinct baseline 
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hazard function but common values for β. The hazard for an individual i , who belongs to 
stratum k is 
𝜆𝑘(𝑡)exp (𝑥(𝑡)𝛽) 
The overall log-likelihood becomes the sum 
                                                          ∑ 𝑙𝑘
𝑘
𝑘=1 (𝛽) 
where 𝑙𝑘(𝛽) is the partial likelihood, but we only sum the subjects in stratum k. This model 
is useful when we deal with recurrent event data. In that case, each recurrence can be 
modelled using a different baseline hazard to control the event dependence. We will 
describe more details in the recurrent and multi-state model section. 
2.4 Andersen-Gill (AG) Model   
The Andersen-Gill model, which will be referred to as the AG model, was 
introduced in the paper by Andersen and Gill. (7) The AG model is based on a counting 
process. A counting process, defined by 𝑁(𝑡) where t is time, is a process which is constant 
between events and only moves one unit at each event time. In the recurrent event setting 
a counting process can be considered as a stochastic process where the occurrence of a 
number of types of disjoint discrete events in time is recorded. (13) The AG model is 
defined as: 
 𝜆(𝑡, 𝑥(𝑡)) = 𝑌(𝑡)𝜆0(𝑡)exp (𝛽𝑥)  
The above equation is the same as the Cox proportional hazards model apart from the 
inclusion on the additional 𝑌(𝑡) term. The term 𝑌(𝑡)  is known as the risk indicator and in 
theory it could also be included in Cox proportional hazards model. The reason that it can 
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be omitted from the Cox proportional hazards model is due to the different definition of 
the risk indicator between the two models. For subject 𝑖 , when the Cox proportional 
hazards model is being used, once subject 𝑖 has suffered the event of interest they are no 
longer at risk of suffering that event so the risk indicator, 𝑌𝑖(𝑡), becomes zero. Therefore, 
for the Cox model once subject 𝑖 has suffered the event of interest they can no longer 
provide any more information for the modelling process. In the AG model the risk indicator 
for subject 𝑖, 𝑌𝑖(𝑡), remains at one for as long as patient 𝑖 is being monitored no matter how 
many or few events they suffer during that period of time. Under AG model, the hazard 
function, 𝜆𝑖(𝑡), of any event for patient 𝑖 is 
𝜆𝑖(𝑡) = 𝑌𝑖(𝑡)𝜆0(𝑡)exp (𝛽𝑥𝑖) , 
Where 
 𝑌𝑖 = {
1, 𝑖𝑓 𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑖 𝑖𝑠 𝑢𝑛𝑑𝑒𝑟 𝑜𝑏𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑜𝑛 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡
0, 𝑖𝑓 𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑖𝑠 𝑐𝑒𝑛𝑠𝑜𝑟𝑒𝑑 𝑏𝑦 𝑡𝑖𝑚𝑒 𝑡                      
  
For the AG model even when subject 𝑖 has suffered the event of interest for the first time 
they can still provide information to use in the modeling process. In the AG model all 
events that subjects suffer are assumed to be independent. There is no distinction made 
between whether an event subject 𝑖  suffers is a first, second or third event as all the events 
are treated the same. The time scale used in the AG model is continuous with it starting at 
time zero, when the subject begins the period of observation, and running until time T, 
when they leave the study. The clock is not reset to zero after an event occurs. As indicated 
previously, subject 𝑖 contributes to the risk set for time 𝑇𝑖 , the total time they are under 
observation, no matter what the event number that is being modelled for and whether 
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patient 𝑖 has or will go onto suffer that number of events. Subject 𝑖 contributes the event 
defining the risk set at times when they suffered events. As events are treated as being 
independent and the number of events suffered is not differentiated between the events 
patient  𝑖  suffers could in effect be treated as single events experienced by n different 
subjects, with n depending on the number of events subject 𝑖 suffered, with the time scale 
starting for each subject at the time of the previous event. The Andersen-Gill model has a 
number of advantages, including the ability to accommodate left-censored data, time-
varying covariates, multiple events, and discontinuous intervals of risks. Under AG model, 
the data for those subjects use the counting process format, where each subject is 
represented by a set of time intervals and event indicators.  
We illustrated these data in Table 1. In this table, SUBJID is the subject ID, 
TSTART is time of previous event or study start, TSTOP is time of event or censoring, 
status is an indicator of event, and TRT is the treatment group.  Subject 1 experienced 4 
events and then was censored at the end of follow-up, so there are 5 corresponding records 
for this subject. In contrast, subject 2 experienced 2 events before being censored, so there 
are only 3 records. 
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Table 1: Data Structure for the AG Model 
SUBJID TSTART TSTOP STATUS TRT 
01-001 0 50 1 1 
01-001 50 125 1 1 
01-001 125 140 1 1 
01-001 140 164 1 1 
01-001 164 365 0 1 
01-002 0 174 1 0 
01-002 174 256 1 0 
01-002 256 365 0 0 
 
AG model can be implanted in SAS using PROC PHREG procedure as described below. 
PROC PHREG COVS=(AGGREGATE); 
WHERE (TSTART<TSTOP); 
MODEL (TSTART, TSTOP)*STATUS(0)=TRT; 
ID SUBJID; 
RUN; 
From the Table 1, you can see, the type of event is ignored as one of the assumptions 
in the AG model. The AG model assumes that all events are identical, which may be too 
strong an assumption, One way to look at this is to examine the cumulative hazards for the 
consecutive events. 
2.5 Wei, Lin, and Weissfeld (WLW) Model  
The Wei, Lin and Weissfeld model, which will be referred to as the WLW model, 
was introduced in the paper by Wei et al. (1989).(8) The WLW model is a marginal model 
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as the correlations among events are not modelled. Under WLW model, the hazard function 
for the jth event for subject i is: 
𝜆𝑖𝑗(𝑡) = 𝑌𝑖𝑗(𝑡)𝜆0j(𝑡)exp (𝛽𝑗𝑥𝑖(t)) , 
Where 
𝑌𝑖𝑗(𝑡) = {
1,   𝑖𝑓 𝑗𝑡ℎ 𝑒𝑣𝑒𝑛𝑡 ℎ𝑎𝑠 𝑛𝑜𝑡 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑑 𝑏𝑦 𝑡𝑖𝑚𝑒 𝑡 𝑓𝑜𝑟 𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑖
0,   𝑖𝑓 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒 𝑜𝑟 𝑐𝑒𝑛𝑠𝑜𝑟𝑒𝑑 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡 𝑓𝑜𝑟 𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑖         
 
In WLW model, 𝑌𝑖𝑗 is at risk indicator or the 𝑗
𝑡ℎ event for subject 𝑖, 𝜆0j(𝑡) is the baseline 
hazard rate function for the jth event, 𝑥𝑖  is a covariate value, which may be time dependent 
for event j, and t represents the time from start of observation. Implying that each event has 
a different unknown underlying hazard function, 𝜆0k(𝑡), and set of parameter estimates, 
𝛽𝑗. In the WLW model only the time since the start of the observation period for patients 
is important and no consideration is given to the time between events or when the previous 
event occurred. When using the WLW model if 𝑗𝑡ℎ events are being modelled for each 
patient is thought to be a risk for those 𝑗𝑡ℎ events. Therefore in the WLW model each 
patient is artificially considered to be at risk of suffering an event whether or not they have 
suffered the preceding event. In this model, the number of strata in the analysis will be 
equal to the maximum number of events a patient reported in the study. Every subject will 
have one observation in each stratum.  
The data structure required for WLW model is illustrated in Table 2. In this data 
set, SUBJID is the subject ID, TSTART is time of previous event or study start, TSTOP is 
time of event or censoring, status is an indicator of event, and TRT is the treatment group.  
Both subjects are represented by the same number of records, namely five as we are 
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interested the first five events observed in the subjects. From the Table 3, you can see, all 
TSTART at study start, and all subjects has the same number of events, for those have 3 
events, they need add two more events in the dataset.  
Table 2: Data Structure for the WLW Model 
SUBJID TSTART TSTOP EVENT STATUS TRT 
01-001 0 50 1 1 1 
01-001 0 125 2 1 1 
01-001 0 140 3 1 1 
01-001 0 164 4 1 1 
01-001 0 365 5 0 1 
01-002 0 174 1 1 0 
01-002 0 256 2 1 0 
01-002 0 365 3 0 0 
01-002 0 365 4 0 0 
01-002 0 365 5 0 0 
 
The WLW model can be implemented in SAS using PROC PHREG as follows: 
Full model: 
PROC PHREG COVS(AGGREGATE); 
MODEL TSTOP*STATUS(0)=trt; 
STRATA EVENT; 
ID SUBJID; 
RUN; 
Or  treatment event interaction model: 
PROC PHREG COVS(AGGREGATE); 
MODEL TSTOP*STATUS(0)=group1-group5; 
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GROUP1=TRT*(EVENT=1); 
GROUP2=TRT*(EVENT=2); 
GROUP3=TRT*(EVENT=3); 
GROUP4=TRT*(EVENT=4); 
GROUP5=TRT*(EVENT=5); 
STRATA EVENT; 
ID SUBJID; 
RUN; 
The option COVS(AGGREGATE) is specified in the RPOC statement to obtain the robust 
sandwich estimate of covariance matrix, and the score residuals used in the computing the 
middle part of the sandwich estimate are aggregate over identical ID values. 
2.6 Prentice, Williams and Peterson (PWP) Model  
The Prentice, Williams and Peterson model, which will be referred to as the PWP 
model, was introduced in the paper by Prentice et al. (9) The PWP model is a conditional 
model and there are two variations of the model. The first variation of this model (PWPa) 
called total, follow-up time conditional model, the hazard function for the jth event for 
subject i is: 
𝜆𝑖𝑗(𝑡, 𝑥(𝑡)) = 𝑌𝑖𝑗(𝑡)𝜆0j(𝑡)exp (𝛽𝑗𝑥𝑖(t)) , 
Where 
 𝑌𝑖𝑗(𝑡) = {
1, 𝑖𝑓 (𝑗 − 1)𝑡ℎ 𝑒𝑣𝑒𝑛𝑡 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑑 𝑏𝑦 𝑡𝑖𝑚𝑒 𝑡 𝑎𝑛𝑑 𝑗𝑡ℎ 𝑒𝑣𝑒𝑛𝑡 ℎ𝑎𝑠 𝑛𝑜𝑡 𝑓𝑜𝑟 𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑖 
0, 𝑖𝑓 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒 𝑜𝑟 𝑐𝑒𝑛𝑠𝑜𝑟𝑒𝑑 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡                                                                             
  
22 
 
 
 
 
Subject is not at risk for the kth event until the patient experienced event k-1st. Like in the 
AG model, time intervals are defined as: (entry time, first event), (first event, second 
event), …, (mth event, last follow-up), but each event is assigned to a separate stratum. 
The use of time-dependent strata means that the underlying hazard function may vary from 
event to event, unlike the AG model, which assumes that all events are identical. The 
second variation of PWP model (PWPb), called conditional gap time model based on the 
gap time from the previous event: 
𝜆𝑖𝑗(𝑡 − 𝑇𝑁(𝑡−)) = 𝑌𝑖𝑗(𝑡)𝜆0j(𝑡 − 𝑇𝑁(𝑡−))exp (𝛽𝑗𝑥𝑖(t)) , 
Where 
 𝑌𝑖𝑗(𝑡) = {
1, 𝑖𝑓 (𝑗 − 1)𝑡ℎ 𝑒𝑣𝑒𝑛𝑡 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑑 𝑏𝑦 𝑡𝑖𝑚𝑒 𝑡 𝑎𝑛𝑑 𝑗𝑡ℎ 𝑒𝑣𝑒𝑛𝑡 ℎ𝑎𝑠 𝑛𝑜𝑡 𝑓𝑜𝑟 𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑖 
0, 𝑖𝑓 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒 𝑜𝑟 𝑐𝑒𝑛𝑠𝑜𝑟𝑒𝑑 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡                                                                             
  
And 𝑇𝑁(𝑡−) is the time of the event just prior to time t.  
The primary difference between the WLW and PWP models is in the definition of the at-
risk indicator and the definition of the strata in the analysis. In the PWP model the at-risk 
indicator, 𝑌𝑖𝑗(t), is defined as zero until the (j-1)th event and only then becomes one. Once 
the jth event occurs, 𝑌𝑖𝑗(t) become 0 again. The PWP model can be seen as a stratified AG 
model with event-specific baseline hazards and a restricted risk set.  
Fitting PWP models, the data structure has to be adjusted slightly. These data 
structure for PWP models is illustrated in Table 3. For PWP models, the subject follows 
the counting process format as shown in Table 1. Similar to what shown in the Table 1 for 
AG model, the number of records representing each subject depends on the number of 
events experienced. In addition to what has included in Table 3, one additional variable 
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called EVENT needs to be added. For PWPa model, the time intervals were modeled, while 
for PWPb model, the time from previous event, gap time was modeled. . 
Table 3: Data Structure for the PWPa Model 
SUBJID TSTART TSTOP GAPTIME EVENT STATUS TRT 
01-001 0 50 50 1 1 1 
01-001 50 125 75 2 1 1 
01-001 125 140 15 3 1 1 
01-001 140 164 24 4 1 1 
01-001 164 365 201 5 0 1 
01-002 0 174 174 1 1 0 
01-002 174 256 82 2 1 0 
01-002 256 365 111 3 0 0 
 
Assuming the maximum number of events observed per subject is 5, the PWPa model can 
be implemented in SAS using PROC PHREG as follows: 
Full Model: 
PROC PHREG; 
MODEL (TSTART, TSTOP)*STATUS(0)=trt; 
STRATA EVENT; 
RUN; 
Or treatment event interaction model: 
PROC PHREG; 
MODEL (TSTART, TSTOP)*STATUS(0)=GROUP1-GROUP5; 
GROUP1=TRT*(EVENT=1); 
GROUP2=TRT*(EVENT=2); 
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GROUP3=TRT*(EVENT=3); 
GROUP4=TRT*(EVENT=4); 
GROUP5=TRT*(EVENT=5); 
STRATA EVENT; 
RUN; 
For PWPb, conditional gap time model, the dependent variable will be time from the 
previous event, instead of time intervals used in PWPa model. The PWPb model can be 
implemented in SAS using PROC PHREG as follows: 
Full Model: 
PROC PHREG; 
MODEL GAPTIME*STATUS(0)=trt; 
STRATA EVENT; 
RUN; 
Or treatment event interaction model: 
PROC PHREG; 
MODELGAPTIME*STATUS(0)=GROUP1-GROUP5; 
GROUP1=TRT*(EVENT=1); 
GROUP2=TRT*(EVENT=2); 
GROUP3=TRT*(EVENT=3); 
GROUP4=TRT*(EVENT=4); 
GROUP5=TRT*(EVENT=5); 
STRATA EVENT; 
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RUN; 
The AG model and PWP models can be used in the analysis of repeated failure 
outcome of the same type, while the approach by the WLW model can be applied to both 
multiple events of the same type and multiple events of different types as long as there is 
not a predetermined ordering. The WLW model has a semi-restricted risk set that allows 
subjects to be at risk for as many events as the maximum number of events reported per 
subject in the study, even if most of the subjects only had one event, which leads to 
overestimation of the treatment effect. For all models, except for PWP models, the robust 
standard errors become inflated when within-subject events are not independent. When the 
model is correctly specified the PWP models and the AG model estimate unbiased 
treatment effect and require similar sample size to obtain the same precision in the 
estimation, while the WLW model estimates biased treatment effect and requires a larger 
sample size. The PWP models and the AG model are considered to be more efficient than 
the WLW model, and require less sample size than the time to first event model. The choice 
of model is dependent on the type and nature of the multiple event structures. 
2.7.  Multi-state Model  
With the clear limitation of aforementioned AG, WLW, and PWP models, which 
does not distinguish the order of hospitalization and death events in HF trial, we are 
interested in exploring multistate model where patients transit from one state to another 
will be an appropriate model to describe all the possible transitions status among recurrent 
hospitalization events and death. Using the multistate model, the first event can be either 
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death or hospitalization, a subject is not at risk for a second hospitalization until the subject 
experiences hospitalization as a first event, and the underlying risk for the transition from 
first hospitalization to death cannot be assumed to be the same for the transition from the 
first hospitalization to a second hospitalization. A similar argument holds for the different 
risks for patients with two or three hospitalization. Let’s assume the maximum number of 
hospitalization is 3 for simplicity of the example, with this, there will be seven possible 
strata. 
Table 4: Description of transition status in the multi-state model 
Transition Stratum Description 
1 Entry to hospitalization e-h1 
2 Hospitalization1 – hospitalization 2 H1-h2 
3 Hospitalization 2 – hospitalization 3 H2-h3 
4 Entry to death e-d 
5 Hosp 1 to death H1-d 
6 Hosp 2 to death H2-d 
7 Hosp 3 to death H3-d 
 
In setting up the dataset for the multistate model one must consider the possible transition 
that a subject could have at a particular state. For example, the subject who has no events, 
only a censoring at time 1 yr. This patient has two possible transition: that is from entry to 
hosp1 or from entry to death. The status in both cases is censoring. Due to the assumption 
of unequal risk for the different transition, the analysis is stratified by transition.  
The dataset for multi-state is illustrated in Table 5. The Transition status is provided for 
each possible transition depending on whether subject had a hospitalization event or death. 
For Subject 01-001, the last event is 3rd hospitalization, thus total 7 transitions are reported, 
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while Subject 01-002, the last event is death after 1st hospitalization, there are 4 transitions 
reported (1, 2, 4, and 5). 
Table 5: Data Structure for the Multi-state Model 
SUBJID TSTART TSTOP TRAN TRANSITION STATUS TRT 
01-001 0 50 1 e-H1 1 1 
01-001 0 50 4 e-d 0 1 
01-001 50 125 2 H1-H2 1 1 
01-001 50 125 5 H1-d 0 1 
01-001 125 140 3 H2-H3 1 1 
01-001 125 140 6 H2-d 0 1 
01-001 140 365 7 H3-d 0 1 
01-002 0 174 1 e-H1 1 2 
01-002 0 174 4 e-d 0 2 
01-002 174 256 2 H1-H2 0 2 
01-002 174 256 5 H1-d 1 2 
 
The multi-state model can be implemented in SAS using PROC PHREG as follows: 
Full model: 
PROC PHREG; 
MODEL (TSTART, TSTOP)*STATUS(0)=trt; 
STRATA TRAN; 
RUN; 
Or treatment transition status interaction model: 
PROC PHREG; 
MODEL (TSTART, TSTOP)*STATUS(0)=GROUP1-GROUP7; 
GROUP1=TRT*(TRAN=1); 
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GROUP2=TRT*(TRAN=2); 
GROUP3=TRT*(TRAN=3); 
GROUP4=TRT*(TRAN=4); 
GROUP5=TRT*(TRAN=5); 
GROUP4=TRT*(TRAN=6); 
GROUP5=TRT*(TRAN=7); 
STRATA TRAN; 
RUN; 
This multistate model fully describes the characteristics of the multiple events of the HF 
endpoints, which separate the order of events between two types. Whether the multistate 
can be simplified to less transition (treat E-H1, H1-H2 and H2-H3 as the same transition, 
or treat E-D, H1-D, and H2-D as the same transition),  by checking the cumulative baseline 
hazards for different transitions using graphical method. If graphical exploration indicates 
that the baseline hazards are not proportional, or statistical test on the interaction term 
between time and transition status are significant, the model with full transition should be 
considered as the best model.  
2.8 Poisson Model 
One natural and clinically interpretable measure of recurrent events is the event rate, 
defined as the number of events divided by the total person-year of experience. The most 
widely used regression model for count data is the log-linear model: 
log(𝐸(𝑌𝑖)) =  𝑙𝑜𝑔𝑡𝑖 + 𝛽
′𝑥𝑖 
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where 𝛽 is a vector of regression coefficient coefficients, 𝑥𝑖 is a vector of covariates for 
subject 𝑖 , so called offset variable 𝑙𝑜𝑔𝑡𝑖  is needed to account for possible different 
observation periods (𝑡𝑖) for different subjects. The popular measures of the adequacy of 
the model fit are deviance and Pearson Chi-square. If statistical model is correct then both 
quantities are asymptotically distributed as 𝜒2  statistics with n-p degrees of freedom (df); 
where n is number of subjects and p is the number of fitted parameters.  
In the case of HF hospitalization and death events, if the events counted on a subject were 
independent, we would expect to be able to use a Poisson distribution as the basis for our 
model. One important characteristics of counts is that the variance tends to increase with 
the average size of the counts. The main feature of the Poisson model is that expected value 
of the random variable 𝑌𝑖 for subject 𝑖 is equal to its variance: 
𝜇 = 𝐸(𝑌𝑖)=Var(𝑌𝑖) 
The Poisson regression is a member of a class of generalized linear models, which 
can be analyzed by Proc Genmod in SAS using DIST=option of Poisson distribution, 
Link=option of log-linear regression model. The adequacy of the model can be tested by 
looking at both deviance and Pearson Chi-square statistics. If the statistics is much higher 
than 1, it suggests that there is a greater variability among event counts than would be 
expected for Poisson distribution. This phenomena is called over-dispersion. The dataset 
for Poisson model is illustrated in Table 6. The data structure requires one record for each 
subject, regardless of the number of events experienced. This record contains the total 
follow-up time and total number of events per subject. For Subject 01-001, during 1 year 
follow-up there are 4 events, while Subject 01-002 has 2 events reported. 
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Table 6: Data Structure for the Poisson Model 
SUBJID NEVENT TIME TRT LOGTIME 
01-001 4 365 1 5.899 
01-002 2 365 2 5.899 
01-003 0 365 1 5.899 
01-004 1 365 2 5.899 
 
The Poisson model can be implemented in SAS using PROC GENMOD as follows: 
PROC GENMOD; 
MODEL nevent=TRT/LINK=LOG DIST=POISSON; 
Run; 
One way to account for overdispersion in Poisson model is to introduce a dispersion 
parameter 𝜙 into the relationship between the variance and the mean 
𝑉𝑎𝑟(𝑌𝑖) = 𝜙𝜇. 
This method can implemented in SAS by introducing an option SCALE= in the model 
statement of Proc Genmod, such as SCALE=DEVIANCE or SCALE=PEARSON. The 
SAS program handles overdispersion as follows: 
PROC GENMOD; 
MODEL nevent=TRT/LINK=LOG DIST=POISSON offset=logtime 
SCALE=DEVIANCE; 
Run; 
2.9  Negative Binomial Model 
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If a Poisson regression model doesn’t fit the data and it appears that the variance of 
Y is increasing much faster than the Poisson model allows, then a simple scale-factor 
adjustment is not appropriate. One way to handle this situation is to fit a parametric model 
that is more dispersed than the Poisson distribution. That is the negative binomial 
distribution. The negative binomial distribution can be derived from the Poisson when the 
mean parameter is not identical for all members of the population, but itself is distributed 
with gamma distribution.  
𝑉𝑎𝑟(𝑌𝑖) = 𝜇 + 𝜅𝜇
2 
Where 𝜅 is an additional distribution parameter that must be estimated or set to a fixed 
value. One important characteristic of the negative binomial distribution is that it naturally 
accounts for overdispersion due to its variance is always greater than the variance of a 
Poisson distribution with the same mean 𝜇. Comparing between negative binomial model 
and Poisson model, when 𝜅 is small, the negative binomial model is close to Poisson model. 
The negative binomial model can be implemented in SAS Proc Genmod with DIST=option 
of NEGBIN in the model statement. The data structure for this model is the same as Poisson 
model requires, one record for each subject, regardless of the number of events experienced. 
This record contains the total follow-up time and total number of events per subject. The 
negative binomial model can be implemented in SAS as follows: 
PROC GENMOD; 
MODEL NEVENT=TRT/LINK=LOG DIST=NEGBIN OFFSET=LOGTIME; 
RUN; 
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A major limitation of this model is it assumes that the recurrent event rate is 
constant over time, which is unlikely to hold in practice. When the dispersion parameter is 
too large, the model will not converge.  
2.10 Single Non-parametric Test for Multiple Outcomes in Hierarchical Order 
Because of the importance of different components of composite endpoints, 
treating them with different order when making pairwise comparison might be more 
information while treating all components equally. Finkelstein and Shoenfeld et al (10) 
proposed an approach to combine longitudinal measure and mortality in a single non-
parametric statistical test using generalized Wilcoxon test with pairwise comparison in a 
fixed observation duration.  Buyse (11) extended the idea behind the U-statistic of the 
Wilcoxon-Mann-Whitney test to perform generalized pairwise comparisons between two 
groups of observations. The principle for the above mentioned methods can be illustrated 
as follows. For two treatment group example, pairwise comparisons can be made from a 
pair of individuals, one from active treatment group, group T, and the other from control 
group, group C. The interested endpoints (single or multiple outcomes) of these two 
individuals are compared and the pair is said to be ‘favorable’ if the outcome of the 
individual in group T is better than that of the individual in group C, ‘unfavorable’ if the 
outcome of the individual in group T is worse than that of the individual in group C, ‘neutral’ 
if there is no difference between the outcome, or ‘uninformative’ if it cannot be determined 
which of the two individuals due to missing data or censoring events for at least one of the 
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two individuals. The favorable definition is usually predefined and usually self-evident. 
The score will be assigned as follows: 
𝑝𝑖𝑗 = {
1      𝑖𝑓 𝑡ℎ𝑒 𝑝𝑎𝑖𝑟 𝑖𝑠 𝑓𝑎𝑣𝑜𝑟𝑎𝑏𝑙𝑒                                 
−1  𝑖𝑓 𝑡ℎ𝑒 𝑝𝑎𝑖𝑟 𝑖𝑠 𝑢𝑛𝑓𝑎𝑣𝑜𝑟𝑎𝑏𝑙𝑒                            
0    𝑖𝑓 𝑡ℎ𝑒 𝑝𝑎𝑖𝑟 𝑖𝑠 𝑛𝑒𝑢𝑡𝑟𝑎𝑙 𝑜𝑟 𝑢𝑛𝑖𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑣𝑒
 
Where 𝑝𝑖𝑗  is the pairwise indicator for the pair formed by the ith individual (i=1,…,n) in 
group T and the jth individual (j=1,…,m) in group C. The Gehan rank for subject is the net 
score (favorable minus unfavorable) and can be defined as: 
𝑅𝑖 = ∑ 𝑝𝑖𝑗,
𝑛+𝑚
𝑗=1,𝑖≠𝑗
𝑖 = 1,… , 𝑛 + 𝑚 
For group T and C, the group Gehan rank is the sum of individual Gehan rank. 
The idea can be extended to pair-wise comparison among stratum whether the study is 
randomized by stratification factors to account for potential confounding factors. In the 
stratified pairwise comparison, the score will be assigned as follows: 
𝑝𝑖𝑗𝑘 = {
1      𝑖𝑓 𝑡ℎ𝑒 𝑝𝑎𝑖𝑟 𝑖𝑠 𝑓𝑎𝑣𝑜𝑟𝑎𝑏𝑙𝑒                                 
−1  𝑖𝑓 𝑡ℎ𝑒 𝑝𝑎𝑖𝑟 𝑖𝑠 𝑢𝑛𝑓𝑎𝑣𝑜𝑟𝑎𝑏𝑙𝑒                            
0    𝑖𝑓 𝑡ℎ𝑒 𝑝𝑎𝑖𝑟 𝑖𝑠 𝑛𝑒𝑢𝑡𝑟𝑎𝑙 𝑜𝑟 𝑢𝑛𝑖𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑣𝑒
 
Where 𝑝𝑖𝑗𝑘 is the pairwise indicator for the pair formed by the 𝑖𝑡ℎ  individual (𝑖 =
1, … , 𝑛𝑘)in group T and the jth individual (𝑗 = 1,… ,𝑚𝑘) in group C in the kth stratum 
(k=1,…,k). 
The test can also be formed based on the win ratio in favor of treatment, which is 
the ratio between the number of favorable pairs and the number of unfavorable pairs. (14, 
15) When the sample size is relatively small, the randomization test can be used to test the 
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treatment benefit based on win ratio. However, when the small size is relatively large, the 
randomization test become less efficient due to taking longer computation time to compute 
the p-value. A large sample normal approximation for the test statistics, under the null 
hypothesis that both group have the same distribution is given by: 
∑𝑅(𝑋𝑗)~ 𝑁 {0,
𝑛𝑚𝑉2
(𝑛 + 𝑚 − 1
} 
Where 𝑉2 = [∑𝑅2(𝑋𝑗) + ∑𝑅
2(𝑌𝑘)]/(𝑛 + 𝑚), with R() the Gehan ranks, 𝑉
2 represents 
the population variance of the Gehan ranks in the pooled sample. (16) 
In HF clinical trials, we are interested in assessing death and hospitalized events 
between two treatment groups. There is a hierarchy of importance of the death versus 
hospitalization events, thus the time to death will be compared in first priority between 
pairwise comparison, followed by the number of hospitalizations or time to first 
hospitalization, then followed by less important outcome if there exists. Table 7 defines 
the rule for combining multiple outcomes in pairwise comparisons. (11) 
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Table 7: Pairwise comparison for Multiple Endpoints in Hierarchical Order 
Outcome with First 
Hierarchy 
Outcome with Second 
Hierarchy  
Pair outcome 
Favorable  No comparison needed Favorable  
Unfavorable  No comparison needed Unfavorable  
Neutral  Favorable Favorable 
Neutral  Unfavorable Unfavorable 
Neutral  uninformative uninformative 
Uninformative  Favorable  Favorable  
Uninformative  Unfavorable  Unfavorable  
Uninformative  Neutral  Neutral  
Uninformative  uninformative uninformative 
 
The same idea described in Table 7 can be extended three level of hierarchical 
endpoints, the third priority comparison will be carried out when the outcome in secondary 
priority comparison is uninformative, the outcome will be decided by the third priority 
pairwise comparison.  
2.10.1 Time to Event Pairwise Comparison between Two Groups  
Let variable X and Y represent right censored variable from group T and C, with 
their corresponding censoring variable W and V, respectively. W=1 or V=1 indicates an 
observed event, and W=0 or V=0 indicates the censored event. The Table 8 displays the 
possible outcomes of pairwise comparisons. (11) 
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Table 8: Pairwise comparison for a time to event variable 
Censoring of X and Y Pairwise comparison   Pair outcome 
𝑊𝑖 = 1 , 𝑉𝑗 = 1  
𝑋𝑖 > 𝑌𝑗 
𝑋𝑖 < 𝑌𝑗 
𝑋𝑖 = 𝑌𝑗  
Favorable  
Unfavorable 
Neutral 
𝑊𝑖 = 0 , 𝑉𝑗 = 1 
𝑋𝑖 > 𝑌𝑗 
𝑋𝑖 < 𝑌𝑗 
𝑋𝑖 = 𝑌𝑗  
Favorable  
uninformative 
uninformative 
𝑊𝑖 = 1 , 𝑉𝑗 = 0 
𝑋𝑖 > 𝑌𝑗 
𝑋𝑖 < 𝑌𝑗 
𝑋𝑖 = 𝑌𝑗  
Uninformative 
unfavorable 
uninformative 
𝑊𝑖 = 0 , 𝑉𝑗 = 0 
𝑋𝑖 > 𝑌𝑗 
𝑋𝑖 < 𝑌𝑗 
𝑋𝑖 = 𝑌𝑗  
Uninformative 
Uninformative 
uninformative 
2.10.2 Continuous Variable Pairwise Comparison between Two Groups  
Let variable X and Y represent continuous from group T and C. For example, X 
and Y represent the total number of hospitalization during fixed follow-up duration, thus 
smaller number of hospitalization indicates favorable outcome in this case. Table 9 displays 
the possible outcomes of pairwise comparisons. (11) 
Table 9: Pairwise comparison for a Continuous Variable 
                               Pairwise comparison Pair outcome 
𝑋𝑖 > 𝑌𝑗 
𝑋𝑖 < 𝑌𝑗 
𝑋𝑖 = 𝑌𝑗 
Unfavorable 
favorable 
Neutral 
 
2.11 Summary  
37 
 
 
 
 
In this chapter we reviewed the statistical methods have been used for analyzing 
time to first event, composite event, and recurrent event data in the medical literatures. The 
methods include the standard KM estimator, Cox Proportional hazards model, recurrent 
models (AG model, WLW, PWP, and multi-state model) with extension of Cox 
proportional hazards model, generalized linear models (Poisson model and negative 
binomial model), and a single non-parametric test combining multiple endpoints with 
hierarchical order for study with fixed follow-up duration. In HF clinical trials, the most 
important outcomes captured in the patients are death and hospitalization events, in order 
to make best use of the mortality and morbidity information collected from the patients, 
the single non-parametric test combining death and hospitalization data in hierarchical 
order appears to be an appealing approach as it treats death in the first priority, but at the 
same time it utilizes the hospitalization data to differentiate treatment benefit between 
groups if survival data is not available for analysis. In addition, multi-state model, an 
extension of Cox proportional hazards model which treats the transition between two 
events differently, for example, it stratifies the event transition state into entry→death, 
entry→1st hospitalization event, 1st hospitalization → 2nd hospitalization, 1st hospitalization 
→ death, 2nd hospitalization → 3rd hospitalization, 2nd  hospitalization → death, etc. With 
this model, it will be able to test the treatment effect at different transition level. Of course, 
there is a limitation that the data has been proportional hazards model although Cox model 
is pretty robust even under the violation of proportional hazard assumptions. We will 
evaluate the performance of hierarchical endpoint using generalized Gehan-Wilcoxon test 
and multi-state model for recurrent event endpoint and compared them with the rest of 
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relatively well-known methods in the simulation studies in Chapter 3 in the fixed follow-
up study design and in Chapter 5 in the variable follow-up study design.   
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Chapter 3 Simulation of Heart Failure Death and Hospitalization Data in Fixed 
Follow-up Duration  
In Chapter 2 the various methods for analyzing different type of HF trial endpoints 
were discussed. We will evaluate those endpoints and statistical methods for analyzing 
those endpoints using simulation study in this chapter. Because hierarchical endpoints 
approached proposed by Finkelstein and Schoenfeld (10) requires the common duration of 
follow-up for the second endpoint, thus for the simplicity, we assumed one year follow-up 
duration for all patients.  
3.1 The Simulation Process 
In order to assess the performance of each method for analyzing different type of 
endpoints under different conditions, we carried out the simulation study. For simplicity, 
we simulated HF clinical trials with the fixed follow-up duration at 1 year for all patients 
and assuming death and hospitalization events are independent. In this case, all patients 
have the same duration of follow-up or died prior to one year cutoff and time to death is 
not associated with hospitalization event rate. The time to death was simulated based on 
Weibull distribution with shape parameter=1, which is exponential distribution, and the 
number of hospitalization and time to each hospitalization was based on Poisson process.  
The parameters used to generate the hospitalization event data with mean hospitalization 
event rate of 𝜇 per year and 1 year mortality rate of  𝑝. In each simulation there were two 
treatment groups indexed by 𝑖, with the control group = 1 and the treatment group = 2. 
Each simulation contained 2n subjects, indexed by j, j = 1,...,n. The recurrent 
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hospitalization events subjects were at risk of suffering from were indexed by k, k = 1,...,k, 
1 for the first event, 2 for the second etc. We used Weibull distribution with shape 
parameter=1 to simulate time to death data, see Equation 3.1, and used Poisson process to 
simulate hospitalization gap times, see Equation 3.2.  
𝑡𝑖𝑗 = −
log(𝑈𝑖𝑗)
− log(1 − 𝑝𝑖)
, 𝑖 = 1, 2, 𝑗 = 1,… , 𝑛, 𝑈𝑖𝑗~𝑈(0,1)                                            (3.1) 
𝑦𝑖𝑗𝑘 = − log(𝑈𝑖𝑗𝑘) /𝑢𝑖; 𝑖 = 1, 2, 𝑗 = 1,… , 𝑛, 𝑘 = 1, . . , 𝐾, 𝑈𝑖𝑗𝑘~𝑈(0,1)                 (3.2)  
Where 𝑡𝑖𝑗is time to death for subject j in treatment group 𝑖,   𝑝𝑖 is the 1 year mortality rate 
in group 𝑖, 𝑈𝑖𝑗 is uniform (0,1) random variable; 𝑦𝑖𝑗𝑘 is the hospitalization gap time for 
subject j for event k in treatment group 𝑖, 𝑢𝑖 is the mean hospitalization rate per year for 
group 𝑖, 𝑈𝑖𝑗𝑘 is uniform (0,1) random variable. The patients will be followed up for a 
maximum of 1 year, and the number of hospitalizations will be conditional on survival 
status. At the end of 1 year follow up if patients who were still alive and were still at risk 
of suffering further hospitalization or death had their time to death and current time interval 
for hospitalization event censored.  
Four groups of simulations were performed: 
1. No treatment effect in both time to death and time to hospitalization  
This simulation will be used to assess the false positive rate (type 1 error) of each 
statistical method for analyzing different type of endpoints. In this group of simulations 
the treatment effect was set to zero, that is, 1 year mortality rate and mean 
hospitalization event rate is equal for both treatment group.  
2. The equal effect size in both time to death and time to hospitalization 
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Simulations were performed to assess the power and performance of each statistical 
test and different endpoint when the treatment benefit in both mortality rate and mean 
hospitalization event is the same.  
3. The effect size in time to death larger than mean hospitalization event rate  
Simulations were performed to assess the power and performance of each statistical 
test and different endpoint when the treatment benefit in reducing mortality rate is 
larger than that reducing mean hospitalization event rate.  
4. The effect size in reducing hospitalization rate is larger than reducing mortality rate   
Simulations were performed to assess the power and performance of each statistical 
test and different endpoint when the treatment benefit in reducing mortality rate is 
smaller than that reducing mean hospitalization event rate.  
3.2. Generating the Time to Death and Recurrent Hospitalization Event Data 
There were 20,000 replicates of each simulation performed for false positive rate 
analysis and 5,000 replicates of each simulation performed for power analysis. The 
individual replicate contained the number of subjects in the control and treatment groups, 
n =100, 150, 200, 250 per group. The mortality rate and mean hospitalization rate used in 
each group of simulations were listed in Table 10.  
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Table 10: Treatment Effect Size Used in Simulation 
Simulation group 1 year mortality rate Mean Hospitalization Rate 
𝑝 𝑢 
1. No Treatment Effect 
Control 0.15 0.75 
Treatment 0.15 0.75 
2. Equal Treatment Effect in Both Mortality and Hospitalization Events (20% reduction) 
Control 0.15 0.75 
Treatment 0.12 0.60 
3a. Unequal Treatment Effect in Both Mortality and Hospitalization Events (Effect in 
reducing Mortality > Effect in reducing Hospitalization rate) 
Control 0.15 0.75 
Treatment 0.10 0.60 
3b. Unequal Treatment Effect in Both Mortality and Hospitalization Events (Effect in 
reducing Mortality < Effect in reducing Hospitalization) 
Control 0.15 0.75 
Treatment 0.12 0.45 
 
We will evaluate following total 14 type of approaches, see Table 11. The first 3 
endpoints (time to single event type endpoint) will be analyzed by standard Cox model. 
The next 5 recurrent event including death will be analyzed using method extended from 
Cox model see details in Chapter 2. The 9th and 10th approaches are based on Poisson and 
negative binomial to evaluate the event rate with fixed duration. The last 4 endpoints are 
proposed based on FS idea to combine time to death with hospitalization information (ie, 
time to first hospitalization or number of hospitalization during first year follow-up) in 
hierarchical manner to distinguish treatment benefit between treatment groups.  The 
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hierarchical endpoints will be analyzed using generalized Gehan-Wilcoxon test via pair-
wise comparison between patients. The test statistics is based on Gehan rank.  In Table 11, 
it described the details of the endpoints and statistical methods for analyzing the data. 
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Table 11: Endpoint and Statistical Method for Analysis 
Index Endpoint Statistical Method 
1 Time to Death Cox Model 
2 Time to First Hosptialization Cox Model 
3 
Time to Death or Time to First 
Hospitalization  
Cox Model 
4 Recurrent hospitalization or death AG model 
5 Recurrent hospitalization or death WLW model 
6 Recurrent hospitalization or death PWPa model 
7 Recurrent hospitalization or death PWPb gap time model 
8 Recurrent hospitalization or death Multi-state model 
9 Recurrent hospitalization or death event Poisson Model  
10 Recurrent hospitalization or death event  Negative Binomial Model 
11 
Hierarchical endpoint with death as first 
priority, followed with number of 
hospitalization  
Pairwise Comparison with 
Generalized Gehan-Wilcoxon 
test 
12 
Hierarchical endpoint with death as first 
priority, followed with time to first 
hospitalization  
Pairwise Comparison with 
Generalized Gehan-Wilcoxon 
test 
13 
Hierarchical endpoint with death as first 
priority, followed with number of 
hospitalization, followed with time to first 
hospitalization 
Pairwise Comparison with 
Generalized Gehan-Wilcoxon 
test 
14 
Hierarchical endpoint with death as first 
priority, followed with time to first 
hospitalization, followed with number of 
hospitalization  
Pairwise Comparison with 
Generalized Gehan-Wilcoxon 
test 
 
3.3 The Simulation Results 
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3.3.1 No treatment effect group of simulation (false positive rate) 
The results for the no treatment effect group of simulations where the treatment 
effect was set to zero are shown in the Table 12. The aim of performing this group of 
simulations was to assess any form of bias in the simulation process. As all the HRs 
approximately equaled to 1 in the Cox model or recurrent event model when sample size 
increases to 500/group, indicating the bias decreases when sample size increases. As the 
treatment effect was set to zero in both mortality and hospitalization event rate that roughly 
5% of the replicates would show a significant effect for both the control and the treatment 
group. Compared to the results obtained from 5000 and 10000 simulations (data not shown) 
with the smaller sample size, the results from 500/group with 20000 simulations 
demonstrated better control of false positive rate. This was reflected in the percentage of 
replicates that were significant in the statistical tests, see Figure 1. 
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                     Figure 1: Percent of Replicates with Significant P-values  
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Table 12: Results for the no treatment effect simulations 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=100/group Time to death, Cox Model 1.08 (0.003) 0.0436 
Time to first hospitalization, Cox Model 1.02 (0.001) 0.05145 
Time to death or first hospitalization, Cox Model 1.02 (0.001) 0.051 
Recurrent hospitalization or death - AG model 1.01 (0.001) 0.05055 
Recurrent hospitalization or death - WLW model 1.02 (0.002) 0.05115 
Recurrent hospitalization or death - PWPa model 1.01 (0.001) 0.04965 
Recurrent hospitalization or death - PWPb model 1.01 (0.001) 0.04985 
Recurrent hospitalization or death - Multistate model 1.01 (0.001) 0.04965 
Hospitalization or death event - Poisson model  0.03595 
Hospitalization or death event - Negative binomial model  0.045623 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.053 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.047 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.047 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.047 
     
N=150/group Time to death, Cox Model 1.05 (0.002) 0.0485 
Time to first hospitalization, Cox Model 1.01 (0.001) 0.0499 
Time to death or first hospitalization, Cox Model 1.01 (0.001) 0.0489 
Recurrent hospitalization or death - AG model 1.01 (0.001) 0.0501 
Recurrent hospitalization or death - WLW model 1.02 (0.001) 0.0501 
Recurrent hospitalization or death - PWPa model 1.01 (0.001) 0.0508 
Recurrent hospitalization or death - PWPb model 1.01 (0.001) 0.0496 
Recurrent hospitalization or death - Multistate model 1.01 (0.001) 0.0508 
Hospitalization or death event - Poisson model  0.0362 
Hospitalization or death event - Negative binomial model  0.0439 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.033 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.036 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.035 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.036 
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Table 12: Results for the no treatment effect simulations 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=200/group Time to death, Cox Model 1.03 (0.002) 0.0472 
Time to first hospitalization, Cox Model 1.01 (0.001) 0.049 
Time to death or first hospitalization, Cox Model 1.01 (0.001) 0.0502 
Recurrent hospitalization or death - AG model 1.01 (0.001) 0.04975 
Recurrent hospitalization or death - WLW model 1.01 (0.001) 0.05015 
Recurrent hospitalization or death - PWPa model 1.01 (0.001) 0.04835 
Recurrent hospitalization or death - PWPb model 1.01 (0.001) 0.04825 
Recurrent hospitalization or death - Multistate model 1.01 (0.001) 0.04835 
Hospitalization or death event - Poisson model  0.0358 
Hospitalization or death event - Negative binomial model  0.0354 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.045 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.043 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.045 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.044 
    
N=250/group Time to death, Cox Model 1.03 (0.002) 0.04935 
Time to first hospitalization, Cox Model 1.01 (0.001) 0.0478 
Time to death or first hospitalization, Cox Model 1.01 (0.001) 0.0472 
Recurrent hospitalization or death - AG model 1 (0.001) 0.0496 
Recurrent hospitalization or death - WLW model 1.01 (0.001) 0.0506 
Recurrent hospitalization or death - PWPa model 1 (0.001) 0.049 
Recurrent hospitalization or death - PWPb model 1 (0.001) 0.04855 
Recurrent hospitalization or death - Multistate model 1 (0.001) 0.049 
Hospitalization or death event - Poisson model  0.0372 
Hospitalization or death event - Negative binomial model  0.04105 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.038 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.042 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.039 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.041 
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Table 12: Results for the no treatment effect simulations 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=500/group Time to death, Cox Model 1.01 (0.001) 0.04965 
Time to first hospitalization, Cox Model 1 (0.001) 0.04815 
Time to death or first hospitalization, Cox Model 1 (0.001) 0.04934 
Recurrent hospitalization or death - AG model 1 (0) 0.049005 
Recurrent hospitalization or death - WLW model 1 (0.001) 0.04995 
Recurrent hospitalization or death - PWPa model 1 (0) 0.04985 
Recurrent hospitalization or death - PWPb model 1 (0) 0.0495 
Recurrent hospitalization or death - Multistate model 1 (0) 0.04985 
Hospitalization or death event - Poisson model  0.0363 
Hospitalization or death event - Negative binomial model  0.04305 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.037 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.035 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.036 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.038 
    
 
 
3.3.2 The equal treatment effect in mortality rate and hospitalization event rate  
The results for the equal treatment effect in both mortality and hospitalization event 
is shown in the Table 13. In this simulation, treatment group has 20% improvement in 
reducing mortality and mean hospitalization event rate. The control group has the same 
estimates as used in no effect simulation, 1 year mortality rate=0.15 and mean 
hospitalization event=0.75, while treatment group with 1 year mortality rate of 0.12 and 
mean hospitalization event rate=0.60. Looking at the HR for time to death, when the sample 
size is small, the estimated HR from time to death is underestimated due to the low 
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mortality rate, a slight change in the event number will have a big impact on HR estimate. 
When the sample size reaches 500/group, the estimates are equal to the expected HR of 
0.80. In 500/group simulation, for the HRs estimated for time to first hospitalization, time 
to mortality or time to first hospitalization, and recurrent hospitalization events or death, 
most methods gave the expected results (HR=0.8) whereas the WLW model (HR=0.75) 
overestimates the treatment effect.  Figure 2 displayed the percentage of replicates with 
significant p-values by different methods. It is true when the sample size the percentage of 
replicates with significant p-value increases in all the studied methods. Due to the sample 
sizes with small mortality rate, the power to detect treatment benefit with estimated hazard 
ratio of 0.8 is very small, between 8-28% with sample size of 200 – 1000, respectively. 
Using the composite endpoint of time to death or time to first hospitalization, it increased 
the number of events for the survival analysis, thus the power is larger than separate 
individual endpoint, time to death only or time to first hospitalization. The recurrent event 
models had the highest power among all 14 methods evaluated. The hierarchical endpoint 
with time to death and time to first hospitalization demonstrated similar power results 
compared to event rate analysis using  Poisson and Negative binomial models.  The 
hierarchical endpoint approach by comparing time to death endpoint, if the death data is 
not comparable, the secondary endpoint such as time to first hospitalization or total number 
of hospitalization will be compared in pair-wise matter, it counted all the death events first 
then augmented by the hospitalization information from patients to help distinguish 
treatment benefit. The power with time to death assessed in first priority, then followed 
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with time to first to hospitalization had higher power compared to composite endpoint 
method (time to death or time to first hospitalization endpoint approach).  
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Figure 2: Percent of replicates with significant pvalue with equal treatment effect in both mortality 
and mean hospitalization rate.  
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Table 13: Results for the equal treatment effect simulations  
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=100/group Time to death, Cox Model 0.85 (0.005) 0.082 
Time to first hospitalization, Cox Model 0.81 (0.002) 0.1924 
Time to death or first hospitalization, Cox Model 0.81 (0.002) 0.218 
Recurrent hospitalization or death - AG model 0.81 (0.002) 0.2872 
Recurrent hospitalization or death - WLW model 0.77 (0.002) 0.2754 
Recurrent hospitalization or death - PWPa model 0.81 (0.002) 0.2786 
Recurrent hospitalization or death - PWPb model 0.81 (0.002) 0.2786 
Recurrent hospitalization or death - Multistate model 0.81 (0.002) 0.2786 
Hospitalization or death event - Poisson model  0.24 
Hospitalization or death event - Negative binomial model  0.2394 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.266 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.22 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.261 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.222 
    
N=150/group Time to death, Cox Model 0.84 (0.004) 0.0992 
Time to first hospitalization, Cox Model 0.81 (0.002) 0.2588 
Time to death or first hospitalization, Cox Model 0.81 (0.002) 0.3038 
Recurrent hospitalization or death - AG model 0.81 (0.002) 0.3956 
Recurrent hospitalization or death - WLW model 0.76 (0.002) 0.377 
Recurrent hospitalization or death - PWPa model 0.81 (0.002) 0.3922 
Recurrent hospitalization or death - PWPb model 0.81 (0.002) 0.3916 
Recurrent hospitalization or death - Multistate model 0.81 (0.002) 0.3922 
Hospitalization or death event - Poisson model  0.3372 
Hospitalization or death event - Negative binomial model  0.3358 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.323 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.292 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.313 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.293 
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Table 13: Results for the equal treatment effect simulations  
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=200/group Time to death, Cox Model 0.81 (0.003) 0.1376 
Time to first hospitalization, Cox Model 0.81 (0.002) 0.3222 
Time to death or first hospitalization, Cox Model 0.8 (0.002) 0.3886 
Recurrent hospitalization or death - AG model 0.8 (0.001) 0.5032 
Recurrent hospitalization or death - WLW model 0.76 (0.002) 0.4774 
Recurrent hospitalization or death - PWPa model 0.8 (0.001) 0.4966 
Recurrent hospitalization or death - PWPb model 0.8 (0.001) 0.4968 
Recurrent hospitalization or death - Multistate model 0.8 (0.001) 0.4966 
Hospitalization or death event - Poisson model  0.4396 
Hospitalization or death event - Negative binomial model  0.439 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.443 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.397 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.45 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.4 
    
N=250/group Time to death, Cox Model 0.81 (0.003) 0.1626 
Time to first hospitalization, Cox Model 0.81 (0.002) 0.3888 
Time to death or first hospitalization, Cox Model 0.8 (0.001) 0.4692 
Recurrent hospitalization or death - AG model 0.8 (0.001) 0.5958 
Recurrent hospitalization or death - WLW model 0.76 (0.001) 0.565 
Recurrent hospitalization or death - PWPa model 0.8 (0.001) 0.5908 
Recurrent hospitalization or death - PWPb model 0.8 (0.001) 0.5898 
Recurrent hospitalization or death - Multistate model 0.8 (0.001) 0.5908 
Hospitalization or death event - Poisson model  0.5332 
Hospitalization or death event - Negative binomial model  0.5324 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.524 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.468 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.516 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.471 
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Table 13: Results for the equal treatment effect simulations  
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=500/group Time to death, Cox Model 0.8 (0.003) 0.277 
Time to first hospitalization, Cox Model 0.8 (0.002) 0.6715 
Time to death or first hospitalization, Cox Model 0.8 (0.001) 0.763 
Recurrent hospitalization or death - AG model 0.8 (0.001) 0.873 
Recurrent hospitalization or death - WLW model 0.75 (0.002) 0.856 
Recurrent hospitalization or death - PWPa model 0.8 (0.001) 0.873 
Recurrent hospitalization or death - PWPb model 0.8 (0.001) 0.8705 
Recurrent hospitalization or death - Multistate model 0.8 (0.001) 0.873 
Hospitalization or death event - Poisson model  0.8275 
Hospitalization or death event - Negative binomial model  0.7905 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.8 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.68 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.74 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.68 
    
56 
 
 
 
 
3.3.3 The unequal treatment effect with larger effect in mortality rate than that in 
hospitalization event rate 
The results for the unequal treatment effect with larger treatment effect in reducing 
mortality than that in reducing mean hospitalization rate is shown in the Table 14. In this 
simulation, treatment group has 33% improvement in reducing mortality and 20% 
reduction in mean hospitalization event rate. The control group has the same estimates as 
used in no effect simulation, 1 year mortality rate=0.15 and mean hospitalization 
event=0.75, while treatment group with 1 year mortality rate of 0.10 and mean 
hospitalization event rate=0.60. Looking at the HR for time to death, with increased 
treatment effect, the power is relatively higher compared with what observed in Section 
3.3.2. The estimated HR of time to death is closed to what used in the simulation when 
sample size increases to 200-500/group. As for HRs estimated for time to first 
hospitalization, time to mortality or time to first hospitalization, and recurrent 
hospitalization events or death, most methods gave the expected results whereas the WLW 
model overestimates the treatment effect (HR in WLW method is smaller than those 
estimated from other recurrent event models).  Figure 3 displayed the percentage of 
replicates with significant p-values by different methods. It is true when the sample size 
the percentage of replicates with significant p-value increases in all the studied methods. 
Using the composite endpoint of time to death or time to first hospitalization when effect 
in mortality is larger than time to first hospitalization, the absolute power increase 
compared to each individual endpoint is much higher than what observed in the Section 
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3.3.2 where the treatment effect is equal in both endpoints. Surprisingly, the hierarchical 
endpoint approach with time to death and time to first hospitalization, it achieves the 
similar or higher power  compared to recurrent event models which considering all the 
event information. In this case, the power with time to death assessed in first priority, then 
followed with time to first to hospitalization had much higher power compared to time to 
death or time to first hospitalization composite endpoint approach.  
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              Figure 3: Percent of replicates with significant pvalue with larger treatment effect in mortality 
than in mean hospitalization rate. 
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Table 14: Results for the unequal treatment effect with larger effect size in mortality 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=100/group Time to death, Cox Model 0.69 (0.004) 0.1604 
Time to first hospitalization, Cox Model 0.81 (0.002) 0.1862 
Time to death or first hospitalization, Cox Model 0.78 (0.002) 0.2738 
Recurrent hospitalization or death - AG model 0.78 (0.002) 0.3462 
Recurrent hospitalization or death - WLW model 0.74 (0.002) 0.3198 
Recurrent hospitalization or death - PWPa model 0.78 (0.002) 0.3376 
Recurrent hospitalization or death - PWPb model 0.78 (0.002) 0.3392 
Recurrent hospitalization or death - Multistate model 0.78 (0.002) 0.3376 
Hospitalization or death event - Poisson model  0.2742 
Hospitalization or death event - Negative binomial model  0.2718 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.337 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.295 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.33 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.295 
    
N=150/group Time to death, Cox Model 0.68 (0.003) 0.2434 
Time to first hospitalization, Cox Model 0.81 (0.002) 0.2628 
Time to death or first hospitalization, Cox Model 0.78 (0.002) 0.381 
Recurrent hospitalization or death - AG model 0.78 (0.001) 0.4958 
Recurrent hospitalization or death - WLW model 0.74 (0.002) 0.4522 
Recurrent hospitalization or death - PWPa model 0.78 (0.001) 0.49 
Recurrent hospitalization or death - PWPb model 0.78 (0.001) 0.4896 
Recurrent hospitalization or death - Multistate model 0.78 (0.001) 0.49 
Hospitalization or death event - Poisson model  0.405 
Hospitalization or death event - Negative binomial model  0.4042 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.527 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.455 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.498 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.456 
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Table 14: Results for the unequal treatment effect with larger effect size in mortality 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=200/group Time to death, Cox Model 0.67 (0.003) 0.3162 
Time to first hospitalization, Cox Model 0.81 (0.002) 0.3224 
Time to death or first hospitalization, Cox Model 0.78 (0.002) 0.4734 
Recurrent hospitalization or death - AG model 0.78 (0.001) 0.597 
Recurrent hospitalization or death - WLW model 0.74 (0.002) 0.5486 
Recurrent hospitalization or death - PWPa model 0.78 (0.001) 0.5938 
Recurrent hospitalization or death - PWPb model 0.78 (0.001) 0.5936 
Recurrent hospitalization or death - Multistate model 0.78 (0.001) 0.5938 
Hospitalization or death event - Poisson model  0.5046 
Hospitalization or death event - Negative binomial model  0.5042 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.596 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.517 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.578 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.517 
    
N=250/group Time to death, Cox Model 0.66 (0.002) 0.3952 
Time to first hospitalization, Cox Model 0.81 (0.002) 0.3784 
Time to death or first hospitalization, Cox Model 0.78 (0.001) 0.5558 
Recurrent hospitalization or death - AG model 0.78 (0.001) 0.6934 
Recurrent hospitalization or death - WLW model 0.74 (0.001) 0.6394 
Recurrent hospitalization or death - PWPa model 0.78 (0.001) 0.6888 
Recurrent hospitalization or death - PWPb model 0.78 (0.001) 0.6878 
Recurrent hospitalization or death - Multistate model 0.78 (0.001) 0.6888 
Hospitalization or death event - Poisson model  0.598 
Hospitalization or death event - Negative binomial model  0.5974 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.708 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.651 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.689 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.65 
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Table 14: Results for the unequal treatment effect with larger effect size in mortality 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=500/group Time to death, Cox Model 0.65 (0.003) 0.679 
Time to first hospitalization, Cox Model 0.8 (0.002) 0.665 
Time to death or first hospitalization, Cox Model 0.77 (0.002) 0.8595 
Recurrent hospitalization or death - AG model 0.77 (0.001) 0.9405 
Recurrent hospitalization or death - WLW model 0.73 (0.002) 0.9095 
Recurrent hospitalization or death - PWPa model 0.77 (0.001) 0.9395 
Recurrent hospitalization or death - PWPb model 0.77 (0.001) 0.94 
Recurrent hospitalization or death - Multistate model 0.77 (0.001) 0.9395 
Hospitalization or death event - Poisson model  0.889 
Hospitalization or death event - Negative binomial model  0.883476 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.92 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.88 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.88 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.88 
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3.3.4 The unequal treatment effect with larger effect in hospitalization rate than 
that in mortality rate 
The results for the unequal treatment effect with larger treatment effect in reducing 
hospitalization rate than that in reducing mortality rate is shown in the Table 15. In this 
simulation, treatment group has 20% improvement in reducing mortality and 40% 
reduction in mean hospitalization event rate. The control group has the same estimates as 
used in no effect simulation, 1 year mortality rate=0.15 and mean hospitalization 
event=0.75, while treatment group with 1 year mortality rate of 0.12 and mean 
hospitalization event rate=0.45. The power to detect time to death between groups is very 
low and similar to what observed in Section 3.3.2, where the effect size of mortality is the 
same as we simulated here. As for HRs estimated for time to first hospitalization, time to 
mortality or time to first hospitalization, and recurrent hospitalization events or death, most 
methods gave the expected results whereas the WLW model overestimates the treatment 
effect.  Figure 4 displayed the percentage of replicates with significant p-values by different 
methods. It is true when the sample size increase the percentage of replicates with 
significant p-value increases in all the studied methods. Using the composite endpoint of 
time to death or time to first hospitalization when effect in mortality is smaller than time 
to first hospitalization, the absolute power increase compared to time to first hospitalization 
is relatively smaller as the majority of events in composite endpoint was attributed to time 
to first hospitalization event. Furthermore, the hierarchical endpoint approach with time to 
death and time to first hospitalization, did not achieve similar size of power compared to 
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recurrent event models. In this case, the power with time to death assessed in first priority, 
then followed with time to first to hospitalization will reduce the impact of counting time 
to first hospitalization as favoring treatment group, which in turn reduce the power. Among 
the recurrent event endpoints, the WLW model overestimated treatment effect compared 
to the rest models. The powers obtained with event rate models are similar to those 
recurrent event models.  
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              Figure 4: Percent of replicates with significant pvalue with larger treatment effect in 
hospitalization rate than in mortality rate 
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Table 15: Results for the unequal treatment effect with larger effect in hospitalization rate 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=100/group Time to death, Cox Model 0.85 (0.005) 0.082 
Time to first hospitalization, Cox Model 0.61 (0.002) 0.6412 
Time to death or first hospitalization, Cox Model 0.64 (0.002) 0.6406 
Recurrent hospitalization or death - AG model 0.64 (0.002) 0.7604 
Recurrent hospitalization or death - WLW model 0.57 (0.002) 0.7576 
Recurrent hospitalization or death - PWPa model 0.64 (0.002) 0.7472 
Recurrent hospitalization or death - PWPb model 0.64 (0.002) 0.747 
Recurrent hospitalization or death - Multistate model 0.64 (0.002) 0.7472 
Hospitalization or death event - Poisson model  0.74 
Hospitalization or death event - Negative binomial model  0.7378 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.624 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.556 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.625 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.556 
    
N=150/group Time to death, Cox Model 0.82 (0.004) 0.1038 
Time to first hospitalization, Cox Model 0.61 (0.002) 0.8192 
Time to death or first hospitalization, Cox Model 0.64 (0.001) 0.8132 
Recurrent hospitalization or death - AG model 0.64 (0.001) 0.902 
Recurrent hospitalization or death - WLW model 0.57 (0.001) 0.9078 
Recurrent hospitalization or death - PWPa model 0.64 (0.001) 0.8996 
Recurrent hospitalization or death - PWPb model 0.64 (0.001) 0.898 
Recurrent hospitalization or death - Multistate model 0.64 (0.001) 0.8996 
Hospitalization or death event - Poisson model  0.8946 
Hospitalization or death event - Negative binomial model  0.8942 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.808 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.748 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.8 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.748 
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Table 15: Results for the unequal treatment effect with larger effect in hospitalization rate 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=200/group Time to death, Cox Model 0.82 (0.003) 0.1362 
Time to first hospitalization, Cox Model 0.61 (0.001) 0.9004 
Time to death or first hospitalization, Cox Model 0.64 (0.001) 0.901 
Recurrent hospitalization or death - AG model 0.64 (0.001) 0.96 
Recurrent hospitalization or death - WLW model 0.57 (0.001) 0.9608 
Recurrent hospitalization or death - PWPa model 0.64 (0.001) 0.9582 
Recurrent hospitalization or death - PWPb model 0.64 (0.001) 0.958 
Recurrent hospitalization or death - Multistate model 0.64 (0.001) 0.9582 
Hospitalization or death event - Poisson model  0.9598 
Hospitalization or death event - Negative binomial model  0.9596 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.864 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.82 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.844 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.82 
    
N=250/group Time to death, Cox Model 0.81 (0.003) 0.1572 
Time to first hospitalization, Cox Model 0.61 (0.001) 0.947 
Time to death or first hospitalization, Cox Model 0.64 (0.001) 0.9504 
Recurrent hospitalization or death - AG model 0.64 (0.001) 0.9876 
Recurrent hospitalization or death - WLW model 0.56 (0.001) 0.9882 
Recurrent hospitalization or death - PWPa model 0.64 (0.001) 0.9874 
Recurrent hospitalization or death - PWPb model 0.64 (0.001) 0.9868 
Recurrent hospitalization or death - Multistate model 0.64 (0.001) 0.9874 
Hospitalization or death event - Poisson model  0.9878 
Hospitalization or death event - Negative binomial model  0.9878 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.93 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.89 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.92 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.89 
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Table 15: Results for the unequal treatment effect with larger effect in hospitalization rate 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=500/group Time to death, Cox Model 0.8 (0.003) 0.2705 
Time to first hospitalization, Cox Model 0.6 (0.001) 1 
Time to death or first hospitalization, Cox Model 0.64 (0.001) 1 
Recurrent hospitalization or death - AG model 0.64 (0.001) 1 
Recurrent hospitalization or death - WLW model 0.56 (0.001) 1 
Recurrent hospitalization or death - PWPa model 0.63 (0.001) 1 
Recurrent hospitalization or death - PWPb model 0.63 (0.001) 1 
Recurrent hospitalization or death - Multistate model 0.63 (0.001) 1 
Hospitalization or death event - Poisson model  1 
Hospitalization or death event - Negative binomial model  0.9995 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.999 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.999 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.999 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.999 
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3.4 Additional Simulation Assuming Correlated Events 
In Section 3.1, for simplicity, we simulated HF clinical trials with the fixed follow-
up duration at 1 year for all patients and assuming death and hospitalization events are 
independent. Actually, in the real life example, the independent assumption of death event 
and hospitalization events is not correct.  In addition, the hospitalization event rate is not 
constant over time. Usually the patients who had death event usually associated with early 
hospitalization event, in addition, the probability to have subsequent hospitalization event 
conditional on the first hospitalization is much higher than the probability to observe the 
first hospitalization. In this case, we simulate the hospitalization events and time to each 
hospitalization event with different hazard rate for those patients survived during the 
follow-up period or who died during the study. In addition, we assume the hazard rate of 
first hospitalization is different from the hazard rate for the subsequent hospitalization 
events. We applied the same simulation process for mortality event, but for hospitalization 
events, the hazard rate for having first hospitalization and subsequent hospitalization event 
is conditional on the survival status at the end of follow-up duration. Instead of assuming 
constant hospitalization event rate using Poisson process, we used Weibull distribution 
with shape parameter=1, which is exponential distribution, to simulate hospitalization 
events in this case. The first hospitalization was simulated as described in Equation 3.3, 
and subsequent hospitalization was simulation as described in Equation 3.4. 
𝑦𝑖𝑗1𝑠 = −
log(𝑈𝑖𝑗1)
𝜆1𝑠𝑖
, 𝑖 = 1, 2, 𝑗 = 1, … , 𝑛, 𝑠 = 0,1, 𝑈𝑖𝑗1~𝑈(0,1)                           (3.3) 
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𝑦𝑖𝑗𝑘𝑠 = −
log(𝑈𝑖𝑗𝑘)
𝜆2𝑠𝑖
; 𝑖 = 1, 2, 𝑗 = 1,… , 𝑛, 𝑠 = 0, 1, 𝑘 = 2, . . , 𝐾, 𝑈𝑖𝑗𝑘~𝑈(0,1)              (3.4)  
Where 𝑦𝑖𝑗1𝑠 is time to first hospitalization for subject j whose survival status 𝑠  in treatment 
group 𝑖,   𝜆1𝑠𝑖 is the hazard for the time to first hospitalization in treatment 𝑖 and survival 
status 𝑠; while 𝑦𝑖𝑗𝑘𝑠 is time to kth (k>1) hospitalization for subject j whose survival status 
𝑠  in treatment group 𝑖,   𝜆2𝑠𝑖 is the hazard for the time to subsequent hospitalization in 
treatment 𝑖 and survival status 𝑠.   𝑈𝑖𝑗𝑘 is uniform (0,1) random variable. For simplicity, 
we assume both treatment group have the same hazard for the subsequent hospitalization 
event. The patients will be followed up for a maximum of 1 year, and the number of 
hospitalizations will be conditional on survival status. At the end of 1 year follow up if 
patients who were still alive and were still at risk of suffering further hospitalization or 
death had their time to death and current time interval for hospitalization event censored.  
Four groups of simulations were performed: 
1. No treatment effect in both time to death and time to hospitalization  
This simulation will be used to assess the false positive rate (type 1 error) of each statistical 
method for analyzing different type of endpoints. In this group of simulations the treatment 
effect was set to zero, that is, 1 year mortality rate and hazard of having first and subsequent 
hospitalization is equal for both treatment group.  
2. The equal effect size in both time to death and hospitalization 
Simulations were performed to assess the power and performance of each statistical test 
and different endpoint when the treatment benefit in both mortality rate and time to first 
and subsequent hospitalization is the same.  
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3. The effect size in time to death larger than time to hospitalization  
Simulations were performed to assess the power and performance of each statistical test 
and different endpoint when the treatment benefit in reducing mortality rate is larger than 
that reducing time to first and subsequent hospitalization.  
4. The effect size in time to hospitalization is larger than reducing mortality rate   
Simulations were performed to assess the power and performance of each statistical test 
and different endpoint when the treatment benefit in reducing mortality rate is smaller than 
that reducing time to hospitalization.  
The mortality rate and hazard of time to first hospitalization and subsequent hospitalization 
under different survival status in each group of simulations were listed in Table 16.  
Table 16:Treatment Effect Size Used in Simulation 
Simulation 
group 
1 year mortality rate Hazard of time to first 
hosp. for the deceased 
Hazard of time to first 
hosp. for the survived 
𝑝 𝜆11 𝜆10 
No Treatment Effect  
Control 0.15 0.5 0.2 
Treatment 0.15 0.5 0.2 
Equal Treatment Effect in Both Mortality and Hospitalization Events 
(20% reduction) 
 
Control 0.15 0.5 0.2 
Treatment 0.12 0.4 0.16 
3a. Unequal Treatment Effect in Both Mortality and Hospitalization 
Events (Effect in reducing Mortality > Effect in reducing 
Hospitalization rate) 
 
Control 0.15 0.5 0.2 
Treatment 0.10 0.4 0.16 
3b. Unequal Treatment Effect in Both Mortality and Hospitalization 
Events (Effect in reducing Mortality < Effect in reducing 
Hospitalization) 
 
Control 0.15 0.5 0.2 
Treatment 0.12 0.25 0.1 
Note: Hazard for subsequent hospitalization assumed to be 0.25 for both treatment and control 
group for simplicity. 
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3.4.1  Results 
Under the scenario where the death event is correlated with time to first hospitalization and 
the hazard of having subsequent hospitalization after the first event is much higher than that of 
having first hospitalization, we evaluated the performance of hierarchical endpoints along with 
other 12 methods except for the negative binomial model for event rate model because the model 
was not converged in most simulations due to larger dispersion parameter. Figure 5 shows the false 
positive rate for each method under 5 different sample sizes conditions. The false positive rate for 
Poisson model were inflated in all scenarios, and the other methods have pretty robust false positive 
rate when sample size increases to 500/group. Table 17 shows the detailed simulations results under 
null hypothesis. 
72 
 
 
 
 
Figure 5: False positive rate with 20000 simulations for each methods 
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Table 17: Results with no treatment benefit 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=100/group Time to death, Cox Model 1.07 (0.006) 0.051 
Time to first hospitalization, Cox Model 1.05 (0.005) 0.0464 
Time to death or first hospitalization, Cox Model 1.03 (0.004) 0.047 
Recurrent hospitalization or death - AG model 1.03 (0.004) 0.0542 
Recurrent hospitalization or death - WLW model 1.03 (0.004) 0.0534 
Recurrent hospitalization or death - PWPa model 1.02 (0.004) 0.0512 
Recurrent hospitalization or death - PWPb model 1.02 (0.004) 0.0518 
Recurrent hospitalization or death - Multistate model 1.02 (0.004) 0.0512 
Hospitalization or death event - Poisson model  0.0662 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.049 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.051 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.051 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.051 
    
N=150/group Time to death, Cox Model 1.04 (0.005) 0.0432 
Time to first hospitalization, Cox Model 1.04 (0.004) 0.049 
Time to death or first hospitalization, Cox Model 1.02 (0.003) 0.0532 
Recurrent hospitalization or death - AG model 1.02 (0.003) 0.0466 
Recurrent hospitalization or death - WLW model 1.03 (0.003) 0.0504 
Recurrent hospitalization or death - PWPa model 1.02 (0.003) 0.0464 
Recurrent hospitalization or death - PWPb model 1.02 (0.003) 0.0462 
Recurrent hospitalization or death - Multistate model 1.02 (0.003) 0.0464 
Hospitalization or death event - Poisson model  0.0598 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.051 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.049 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.051 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.049 
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Table 17: Results with no treatment benefit 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=200/group Time to death, Cox Model 1.03 (0.004) 0.0462 
Time to first hospitalization, Cox Model 1.03 (0.003) 0.0458 
Time to death or first hospitalization, Cox Model 1.02 (0.003) 0.0452 
Recurrent hospitalization or death - AG model 1.02 (0.003) 0.0456 
Recurrent hospitalization or death - WLW model 1.02 (0.003) 0.0462 
Recurrent hospitalization or death - PWPa model 1.01 (0.002) 0.0464 
Recurrent hospitalization or death - PWPb model 1.01 (0.002) 0.0462 
Recurrent hospitalization or death - Multistate model 1.01 (0.002) 0.0464 
Hospitalization or death event - Poisson model  0.058 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.043 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.042 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.043 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.042 
    
N=250/group Time to death, Cox Model 1.03 (0.003) 0.0504 
Time to first hospitalization, Cox Model 1.02 (0.003) 0.0462 
Time to death or first hospitalization, Cox Model 1.02 (0.002) 0.052 
Recurrent hospitalization or death - AG model 1.01 (0.002) 0.0502 
Recurrent hospitalization or death - WLW model 1.02 (0.003) 0.0518 
Recurrent hospitalization or death - PWPa model 1.01 (0.002) 0.052 
Recurrent hospitalization or death - PWPb model 1.01 (0.002) 0.0514 
Recurrent hospitalization or death - Multistate model 1.01 (0.002) 0.052 
Hospitalization or death event - Poisson model  0.064 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.059 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.054 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.057 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.054 
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Table 17: Results with no treatment benefit 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=500/group Time to death, Cox Model 1.01 (0.002) 0.05 
Time to first hospitalization, Cox Model 1.01 (0.002) 0.0476 
Time to death or first hospitalization, Cox Model 1.01 (0.002) 0.0428 
Recurrent hospitalization or death - AG model 1.01 (0.002) 0.0474 
Recurrent hospitalization or death - WLW model 1.01 (0.002) 0.046 
Recurrent hospitalization or death - PWPa model 1.01 (0.001) 0.048 
Recurrent hospitalization or death - PWPb model 1.01 (0.001) 0.0482 
Recurrent hospitalization or death - Multistate model 1.01 (0.001) 0.048 
Hospitalization or death event - Poisson model  0.0602 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.038 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.036 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.037 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.036 
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Figures 6, 7, and 8 and Tables 18, 19, and 20 show the power performance of each 
individual method under three different assumptions: the equal treatment effect in mortality and 
time to first hospitalization in both survival status between treatment and control group, better 
treatment effect in reducing mortality than in preventing early admission to hospital, and better 
treatment effect in preventing early admission to hospital than in reducing mortality rate, 
respectively. The results indicate that the power increases when sample size increases, in addition, 
the Poisson model showed higher power to detect the overall treatment benefit when the overall 
treatment benefit was not overly weighted by the hospitalization events. Under equal treatment 
effect size scenario, the performance of hierarchical endpoint approach is equivalent to those 
recurrent event model and multi-state model, see Figure 6.  
Figure 6: Power results of the second group simulation: equal treatment effect  
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Table 18: Power of the second group simulation: equal treatment effect size 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=100/group Time to death, Cox Model 0.86 (0.008) 0.0845 
Time to first hospitalization, Cox Model 0.83 (0.006) 0.0955 
Time to death or first hospitalization, Cox Model 0.82 (0.005) 0.125 
Recurrent hospitalization or death - AG model 0.82 (0.005) 0.1315 
Recurrent hospitalization or death - WLW model 0.81 (0.005) 0.1305 
Recurrent hospitalization or death - PWPa model 0.83 (0.005) 0.132 
Recurrent hospitalization or death - PWPb model 0.83 (0.005) 0.13 
Recurrent hospitalization or death - Multistate model 0.83 (0.005) 0.132 
Hospitalization or death event - Poisson model  0.156 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.13 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.126 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.127 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.126 
    
N=150/group Time to death, Cox Model 0.83 (0.006) 0.1035 
Time to first hospitalization, Cox Model 0.81 (0.005) 0.1195 
Time to death or first hospitalization, Cox Model 0.81 (0.004) 0.177 
Recurrent hospitalization or death - AG model 0.81 (0.004) 0.1715 
Recurrent hospitalization or death - WLW model 0.8 (0.004) 0.18 
Recurrent hospitalization or death - PWPa model 0.82 (0.004) 0.172 
Recurrent hospitalization or death - PWPb model 0.82 (0.004) 0.167 
Recurrent hospitalization or death - Multistate model 0.82 (0.004) 0.172 
Hospitalization or death event - Poisson model  0.199 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.171 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.175 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.173 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.175 
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Table 18: Power of the second group simulation: equal treatment effect size 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=200/group Time to death, Cox Model 0.82 (0.005) 0.127 
Time to first hospitalization, Cox Model 0.81 (0.005) 0.144 
Time to death or first hospitalization, Cox Model 0.81 (0.003) 0.217 
Recurrent hospitalization or death - AG model 0.81 (0.003) 0.22 
Recurrent hospitalization or death - WLW model 0.8 (0.004) 0.2265 
Recurrent hospitalization or death - PWPa model 0.82 (0.003) 0.2175 
Recurrent hospitalization or death - PWPb model 0.82 (0.003) 0.217 
Recurrent hospitalization or death - Multistate model 0.82 (0.003) 0.2175 
Hospitalization or death event - Poisson model  0.256 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.229 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.23 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.227 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.23 
    
N=250/group Time to death, Cox Model 0.81 (0.005) 0.166 
Time to first hospitalization, Cox Model 0.8 (0.004) 0.189 
Time to death or first hospitalization, Cox Model 0.8 (0.003) 0.2605 
Recurrent hospitalization or death - AG model 0.81 (0.003) 0.2745 
Recurrent hospitalization or death - WLW model 0.79 (0.003) 0.275 
Recurrent hospitalization or death - PWPa model 0.81 (0.003) 0.267 
Recurrent hospitalization or death - PWPb model 0.81 (0.003) 0.266 
Recurrent hospitalization or death - Multistate model 0.81 (0.003) 0.267 
Hospitalization or death event - Poisson model  0.3145 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.267 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.268 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.266 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.268 
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Table 18: Power of the second group simulation: equal treatment effect size 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=500/group Time to death, Cox Model 0.8 (0.003) 0.27 
Time to first hospitalization, Cox Model 0.79 (0.003) 0.3635 
Time to death or first hospitalization, Cox Model 0.8 (0.002) 0.499 
Recurrent hospitalization or death - AG model 0.8 (0.002) 0.5065 
Recurrent hospitalization or death - WLW model 0.79 (0.002) 0.51 
Recurrent hospitalization or death - PWPa model 0.81 (0.002) 0.4995 
Recurrent hospitalization or death - PWPb model 0.81 (0.002) 0.501 
Recurrent hospitalization or death - Multistate model 0.81 (0.002) 0.4995 
Hospitalization or death event - Poisson model  0.55 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.508 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.505 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.51 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.505 
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Under the scenario where the treatment effect size in reducing mortality is much larger 
than effect in preventing early admission to hospital, the performance of hierarchical endpoint is 
better than composite endpoint and other recurrent event models, in Figure 7 and Table 19. 
Figure 7: Power of the third group simulation: better treatment effect in mortality 
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Table 19: Results for third group simulation: larger treatment effect in mortality  
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=100/group Time to death, Cox Model 0.69 (0.007) 0.1785 
Time to first hospitalization, Cox Model 0.82 (0.007) 0.1085 
Time to death or first hospitalization, Cox Model 0.75 (0.005) 0.2075 
Recurrent hospitalization or death - AG model 0.75 (0.005) 0.2195 
Recurrent hospitalization or death - WLW model 0.74 (0.005) 0.2165 
Recurrent hospitalization or death - PWPa model 0.76 (0.005) 0.217 
Recurrent hospitalization or death - PWPb model 0.76 (0.005) 0.221 
Recurrent hospitalization or death - Multistate model 0.76 (0.005) 0.217 
Hospitalization or death event - Poisson model  0.2535 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.229 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.229 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.23 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.229 
    
N=150/group Time to death, Cox Model 0.68 (0.005) 0.256 
Time to first hospitalization, Cox Model 0.81 (0.005) 0.1205 
Time to death or first hospitalization, Cox Model 0.75 (0.004) 0.2895 
Recurrent hospitalization or death - AG model 0.75 (0.004) 0.293 
Recurrent hospitalization or death - WLW model 0.74 (0.004) 0.286 
Recurrent hospitalization or death - PWPa model 0.76 (0.004) 0.2945 
Recurrent hospitalization or death - PWPb model 0.76 (0.004) 0.2895 
Recurrent hospitalization or death - Multistate model 0.76 (0.004) 0.2945 
Hospitalization or death event - Poisson model  0.336 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.32 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.323 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.321 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.323 
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Table 19: Results for third group simulation: larger treatment effect in mortality  
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=200/group Time to death, Cox Model 0.67 (0.005) 0.314 
Time to first hospitalization, Cox Model 0.8 (0.005) 0.1685 
Time to death or first hospitalization, Cox Model 0.74 (0.003) 0.3605 
Recurrent hospitalization or death - AG model 0.74 (0.003) 0.375 
Recurrent hospitalization or death - WLW model 0.73 (0.003) 0.3635 
Recurrent hospitalization or death - PWPa model 0.75 (0.003) 0.3755 
Recurrent hospitalization or death - PWPb model 0.75 (0.003) 0.3745 
Recurrent hospitalization or death - Multistate model 0.75 (0.003) 0.3755 
Hospitalization or death event - Poisson model  0.4195 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.405 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.399 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.399 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.399 
    
N=250/group Time to death, Cox Model 0.66 (0.004) 0.4045 
Time to first hospitalization, Cox Model 0.79 (0.004) 0.213 
Time to death or first hospitalization, Cox Model 0.74 (0.003) 0.4555 
Recurrent hospitalization or death - AG model 0.74 (0.003) 0.457 
Recurrent hospitalization or death - WLW model 0.73 (0.003) 0.4445 
Recurrent hospitalization or death - PWPa model 0.75 (0.003) 0.462 
Recurrent hospitalization or death - PWPb model 0.75 (0.003) 0.4625 
Recurrent hospitalization or death - Multistate model 0.75 (0.003) 0.462 
Hospitalization or death event - Poisson model  0.505 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.484 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.488 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.486 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.488 
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Table 19: Results for third group simulation: larger treatment effect in mortality  
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=500/group Time to death, Cox Model 0.65 (0.003) 0.6795 
Time to first hospitalization, Cox Model 0.77 (0.003) 0.399 
Time to death or first hospitalization, Cox Model 0.73 (0.002) 0.74 
Recurrent hospitalization or death - AG model 0.73 (0.002) 0.7665 
Recurrent hospitalization or death - WLW model 0.72 (0.002) 0.7475 
Recurrent hospitalization or death - PWPa model 0.74 (0.002) 0.7805 
Recurrent hospitalization or death - PWPb model 0.74 (0.002) 0.7765 
Recurrent hospitalization or death - Multistate model 0.74 (0.002) 0.7805 
Hospitalization or death event - Poisson model  0.7995 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.784 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.78 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.778 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.78 
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Under the scenario where the treatment effect size in reducing mortality is much smaller 
than effect in preventing early admission to hospital, the performance of hierarchical endpoint did 
not perform as well as the composite endpoint and other recurrent event model, see Figure 8 and 
Table 20. 
Figure 8:  Power results from fourth set of simulation  
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Table 20: Results for fourth group simulation: larger treatment effect in hospitalization  
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=100/group Time to death, Cox Model 0.86 (0.008) 0.082 
Time to first hospitalization, Cox Model 0.52 (0.005) 0.4265 
Time to death or first hospitalization, Cox Model 0.66 (0.004) 0.3545 
Recurrent hospitalization or death - AG model 0.66 (0.004) 0.3835 
Recurrent hospitalization or death - WLW model 0.63 (0.004) 0.401 
Recurrent hospitalization or death - PWPa model 0.68 (0.004) 0.3515 
Recurrent hospitalization or death - PWPb model 0.68 (0.004) 0.355 
Recurrent hospitalization or death - Multistate model 0.68 (0.004) 0.3515 
Hospitalization or death event - Poisson model  0.4145 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.328 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.328 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.329 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.328 
    
N=150/group Time to death, Cox Model 0.83 (0.006) 0.1095 
Time to first hospitalization, Cox Model 0.51 (0.004) 0.599 
Time to death or first hospitalization, Cox Model 0.64 (0.003) 0.514 
Recurrent hospitalization or death - AG model 0.65 (0.003) 0.5165 
Recurrent hospitalization or death - WLW model 0.62 (0.003) 0.5445 
Recurrent hospitalization or death - PWPa model 0.67 (0.003) 0.4855 
Recurrent hospitalization or death - PWPb model 0.67 (0.003) 0.4825 
Recurrent hospitalization or death - Multistate model 0.67 (0.003) 0.4855 
Hospitalization or death event - Poisson model  0.5585 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.467 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.466 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.469 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.466 
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Table 20: Results for fourth group simulation: larger treatment effect in hospitalization  
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=200/group Time to death, Cox Model 0.81 (0.005) 0.14 
Time to first hospitalization, Cox Model 0.51 (0.003) 0.7305 
Time to death or first hospitalization, Cox Model 0.64 (0.003) 0.6405 
Recurrent hospitalization or death - AG model 0.64 (0.003) 0.641 
Recurrent hospitalization or death - WLW model 0.61 (0.003) 0.676 
Recurrent hospitalization or death - PWPa model 0.66 (0.003) 0.6135 
Recurrent hospitalization or death - PWPb model 0.66 (0.003) 0.608 
Recurrent hospitalization or death - Multistate model 0.66 (0.003) 0.6135 
Hospitalization or death event - Poisson model  0.689 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.577 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.577 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.575 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.577 
    
N=250/group Time to death, Cox Model 0.8 (0.004) 0.163 
Time to first hospitalization, Cox Model 0.5 (0.003) 0.836 
Time to death or first hospitalization, Cox Model 0.63 (0.003) 0.7645 
Recurrent hospitalization or death - AG model 0.63 (0.003) 0.7695 
Recurrent hospitalization or death - WLW model 0.6 (0.003) 0.8 
Recurrent hospitalization or death - PWPa model 0.66 (0.003) 0.7325 
Recurrent hospitalization or death - PWPb model 0.66 (0.003) 0.735 
Recurrent hospitalization or death - Multistate model 0.66 (0.003) 0.7325 
Hospitalization or death event - Poisson model  0.8115 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.689 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.692 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.694 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.692 
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Table 20: Results for fourth group simulation: larger treatment effect in hospitalization  
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=500/group Time to death, Cox Model 0.8 (0.003) 0.285 
Time to first hospitalization, Cox Model 0.5 (0.002) 0.9835 
Time to death or first hospitalization, Cox Model 0.63 (0.002) 0.9525 
Recurrent hospitalization or death - AG model 0.64 (0.002) 0.95 
Recurrent hospitalization or death - WLW model 0.61 (0.002) 0.965 
Recurrent hospitalization or death - PWPa model 0.66 (0.002) 0.934 
Recurrent hospitalization or death - PWPb model 0.66 (0.002) 0.9345 
Recurrent hospitalization or death - Multistate model 0.66 (0.002) 0.934 
Hospitalization or death event - Poisson model  0.963 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.91 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.912 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.912 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.912 
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3.5  Summary 
From the results of the no treatment effect group of simulations it was seen that the 
simulation process was unbiased when the sample size is reasonably large. All studied 
approaches achieved robust false positive rate around 5% except the Poisson model has 
slight inflated false positive rate under the scenario where time to hospitalization was 
associated with survival status simulation.  
In general, the recurrent event model and Poisson and negative binomial model had 
higher power to detect treatment benefit compared to individual endpoint, composite 
endpoint, and hierarchical endpoint. However, when treatment benefit in mortality is larger 
than in reducing hospitalization rate, the hierarchical endpoint with time to death assessed 
in the first priority, followed with comparing time to first hospitalization, achieved the 
highest power even larger than recurrent event model and composite endpoint approach 
under both constant hospitalization event rate using Poisson process simulation and under 
the situation whether the hazard of having first hospitalization and subsequent 
hospitalization was different and the hospitalization rate was associated with survival status. 
The reason is that death event will be outweighed the importance of hospitalization events 
in the hierarchical approach compared to the recurrent event model or Poisson or negative 
binomial model where the death event is considered the same as any of hospitalization 
event. Although the computation for pair-wise comparison for hierarchical endpoint is 
much slow, with the robust performance under both scenarios, this approach can provide 
the clinician better understanding the overall benefit of tested drugs where it weighs the 
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importance prolong survival in the higher priority compared to other methods treating the 
death events equally as the hospitalization event.  
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Chapter 4 Evaluating HF Endpoints in the DIG Trial With One-Year Follow-up  
In this chapter we will evaluate the efficiency of comparing the treatment benefit 
of Digoxin using different type of endpoints compared to composite endpoint of time to 
death or time to first hospitalization. To mimic the design of simulation study used in 
Chapter 3, we will censor DIG study at one year. If death or hospitalization occurred after 
1 year were censored at 1 year so that all the patients have the common duration of follow-
up.  
4.1 Methods: 
4.1.1 Study design and patients 
The Digoxin Investigation Group (DIG) Trial was a randomized, double-blind, 
multicenter trial with more than 300 centers in the United States and Canada participating. 
The purpose of the trial was to examine the safety and efficacy of Digoxin in treating 
patients with congestive heart failure in sinus rhythm. In the main DIG trial, 6800 
ambulatory patients with chronic heart failure (ejection fraction <=45%) in normal sinus 
rhythm were randomized to receive digoxin or placebo during 1991-1993 and were 
followed for an average of 37 months. The primary outcome in the main DIG trial was all-
cause mortality. For the current analysis we evaluated following endpoints: all-cause 
mortality, time to first hospitalization, time to death or time to first to first hospitalization, 
death or recurrent hospitalization with different recurrent event models, death or recurrent 
hospitalization events with Poisson or negative binomial model, hierarchical endpoints 
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with mortality as first priority then followed with time to first hospitalization or number of 
hospitalization using generalized Gehan-Wilcoxon test.  
4.2 Results 
Mortality and Frequency of Hospitalization During First Year Follow-up 
The number of death and frequencies of hospitalization are presented in Table 21.  
Of the 6800 patients with chronic heart failure randomized, 427 (12.5%) and 378 (11.1%) 
deaths were observed in placebo and digoxin group, respectively, during one year follow-
up.  
Table 21: Frequency of Death and Hospitalization during First Year Follow-up 
 Digoxin (N=3397) Placebo (N=3403) 
Number of death 378 (11.1%) 427 (12.5%) 
Number of hospitalizations   
                     0 2171 (63.9%) 2055 (60.4%) 
                     1 683 (20.1%) 734 (21.6%) 
                     2 288 (8.5%) 330 (9.7%) 
                     3 148 (4.4%) 132 (3.9) 
                     4 54 (1.6%) 64 (1.9%) 
                     5 23 (0.7%) 47 (1.4%) 
                 >=6 30 (0.9%) 41 (1.2%) 
 
Figure 9 shows the KM curve by treatment group. Table 22 displayed the log-rank 
test and Cox model results. The log-rank p-value is 0.064 and hazard ratio is 0.88. The 
results indicated that there is no statistical significance in 1-year mortality rate between 
two groups. 
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Table 22:  Time to Death at the end of one year follow-up by treatment group 
 Placebo 
(N=3403) 
Digoxin 
(N=3397) 
Patients Censored n(%) 2976 (87.5) 3019 (88.9) 
Log-Rank p-value 0.0640  
HR (95% CI) 0.878 (0.764, 1.008)  
 
Figure 9:  KM Curve of 1-year mortality by treatment group 
 
 
The frequencies of hospitalizations are presented in Table 21. Of the 6800 patients 
randomized, 1348 (39.9%) and 1226 (43.9%) had at least one hospitalization during first 
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year of the study, in placebo and digoxin group, respectively. The frequencies with 5 or 
more hospitalizations are 1.6% and 2.6% in digoxin and placebo, respectively. Because of 
small patients with more frequent hospitalization during the first study, we will restrict the 
recurrent event analysis up to the 4th hospitalization. 
The result of time to first hospitalization was shown in Table 23 and KM curve of time to 
first hospitalization was displayed in Figure 10. 
Table 23: Time to First Hospitalization at the end of one year follow-up by treatment group 
 Placebo 
(N=3403) 
Digoxin 
(N=3397) 
Patients Censored n(%) 1908 (56.1) 2007 (59.1) 
Log-Rank p-value 0.0016  
HR (95% CI) 0.889 (0.826, 0.956)  
 
Although the estimated HR for time to first hospitalization is similar to the one for 
1 year mortality, due to the large sample size, the log-rank p-values showed statistical 
significance (p=0.0016).  
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Figure 10: KM curve for time to first hospitalization between two groups. 
 
 
Composite Endpoint: time to death or time to first hospitalization 
The Table 24 shows the results from log-rank test and cox model for comparing 
two groups using composite endpoint, time to death or time to first hospitalization. With 
composite endpoints, there are 1390 (40.9%) and 1495(44.0%) events in digoxin and 
placebo group, respectively.  
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Table 24: Time to Death or time to First Hospitalization at the end of one year follow-up by treatment 
group 
 Placebo 
(N=3403) 
Digoxin 
(N=3397) 
Patients Censored n(%) 1908 (56.0) 2007 (59.1) 
Log-Rank p-value 0.0016  
HR (95% CI) 0.889 (0.826, 0.956)  
 
Compared to time to first hospitalization event only, using the composite endpoint, 
it increased the number of events slightly as the death event was small in both groups in 
overall, however the log-rank test and Hazard ratio is identical to what estimated for time 
to first hospitalization analysis.  The Figure 11 shows the KM curve by treatment group for 
the composite endpoint. 
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Figure 11: Time to Death or Time to First Hospitalization at 1 –year follow-up 
 
 
Recurrent hospitalizations or death event analysis 
The results for the four recurrent event models and one multistate model as well as 
the time to first event Cox models are shown in Table 25.  
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Table 25: The time-to-first event Cox model and recurrent event analyses based on the first 4 
hospitalizations or death during 1 year of DIG trial. 
Model Hazard ratio, 
95% CI 
P-value 
Time to death – Cox model 0.88 (0.76, 1.01) 0.0644 
Time to first hospitalization – Cox model 0.86 (0.79, 0.93) <0.0001 
Time to death or time to first hospitalization – Cox 
model 
0.89 (0.83, 0.96) 0.0015 
Recurrent hospitalizations or death – AG model 0.88 (0.83, 0.93) 0.0006 
Recurrent hospitalizations or death – WLW model 0.85 (0.78, 0.93) 0.0002 
Recurrent hospitalizations or death – PWPa model 0.93 (0.88, 0.98) 0.0059 
Recurrent hospitalizations or death – PWPb model 0.92 (0.87, 0.97) 0.0014 
Recurrent hospitalizations or death – Multistate 
model 
0.93 (0.88, 0.98) 0.0059 
 
Because the frequencies of having more than 5 hospitalization in one year is very 
low, the recurrent event analysis was only limited to the first four hospitalizations. The AG 
model with robust standard errors gave an estimated hazard ratio of 0.88 (95% CI: 0.83 - 
0.93), WLW model gave an estimated hazard ratio of 0.85 (95% CI: 0.78 – 0.93), PWPa 
model gave the HR of 0.93 (95% CI: 0.88 – 0.98), and PWPb model gave the HR of 0.92 
(95% CI: 0.87 – 0.97). The multi-state model accounting for different transition among the 
start of the study, sequence of death events after different number of hospitalization, gave 
the estimated HR of 0.93 (95% CI: 0.88 – 0.98). Overall, the treatment effect obtained from 
different recurrent event models are consistent, the magnitude of hazard ratios are broadly 
similar, with WLW model slightly overestimated treatment benefit, while PWPa, PWPb 
and multi-state model slightly underestimated treatment benefit compared to time to first 
hospitalization hazard ratio.  
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The results for Poisson and negative binomial model for hospitalization and death event 
rate within first year of the treatment are shown in Table 26.   
Table 26: Poisson and Negative Binomial Model Results for composite hospitalization and death event 
rate within first year of follow-up 
Model Rate ratio, 95% CI P-value 
Poisson Model 0.89 (0.84, 0.94) <0.0001 
Negative binomial model 0.89 (0.83, 0.96) 0.0018 
 
The Poisson model gave a rate ratio for the composite of recurrent hospitalizations 
and death of 0.89 (95% CI: 0.84 – 0.94, P <0.0001) by comparing digoxin group with 
placebo. The negative binomial model yielded an estimated rate ratio of 0.89 (95% CI: 0.83 
– 0.96, P =0.0018). Compared to the results obtained from the recurrent event model results, 
the rate ratios from event rate models are consistent with the recurrent event model when 
accounting for recurrent hospitalization events and death during 1 year follow-up.  
The hierarchical endpoint Method 
The results of the hierarchical endpoints using generalized Gehan-Wilcoxon test 
are shown in the Table 27. Four hierarchical endpoints with death as the first priority 
components were evaluated, first two with two components, and another two with three 
components. In addition to the p-values generated from the generalized Gehan-Wilcoxon 
test, the win ratio defined as the total number of better outcomes divided by the total 
number of worse outcomes were also provided. 
Table 27: Hierarchical Endpoints using generalized Gehan-Wilcoxon Test and Ratio Poisson and 
Negative Binomial Model Results for composite hospitalization and death event rate within first year 
of follow-up 
99 
 
 
 
 
Hierarchical Endpoints Win ratio P-value 
Death, time to first hospitalization 1.13 0.0013 
Death, Number of hospitalizations 1.12 0.005 
Death, time to first hospitalization, 
Number of hospitalizations 
1.13 0.0013 
Death, Number of hospitalizations, time to 
first hospitalization 
1.12 0.0027 
 
The results indicated that with hierarchical endpoints by comparing death events in 
the first priority followed by either the time to first hospitalization or number of 
hospitalizations in pairwise matter, the digoxin group has statistically significant better 
outcome compared to placebo group with win ratio of 1.13 and 1.12 and generalized 
Gehan-Wilcoxon test p-value of 0.0013 and 0.005 for hierarchical endpoints death 
followed with time to first hospitalization, and death followed by the number of 
hospitalizations, respectively.  
4.3 Discussion: 
Out analysis of DIG trial data with one year of follow-up show that methods that 
take account of recurrent hospitalizations and death together can demonstrate a consistent 
and robust treatment effect benefit that the conventional time to first event analysis. 
Although the efficiency of detecting treatment benefit in the recurrent event endpoints and 
hierarchical endpoints appear not that dramatic compared to the conventional time to first 
event analysis in our analysis, because the sample size of DIG trial is so large that has the 
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sufficient power to detect the treatment benefit from the placebo group. From our 
simulation study showed in the Chapter 3, when the sample size is relative smaller, the 
benefit of using recurrent event endpoints will be more pronounced compared to the time 
to first event endpoint.  
The motivation for considering these alternative approaches to analysis of clinical 
outcomes is that many cardiovascular diseases are chronic diseases characterized by a 
relatively long period before death during which multiple non-fatal but clinical relevant 
events occur, often leading to hospitalizations. Although time to first event is simple and 
more familiar by many clinicians and easy to interpret the results, in our view, an analysis 
that takes account of all of the disease related cardiovascular events that occur as a result 
of a disease progression, rather than just the first event, gives a better description of the 
true burden of the disease and is also the real indicator for treatment effect.  
These analysis of DIG trial data show that digoxin not only reduces the risk of first 
admission to hospital, but also decreases the incidence of repeated hospitalization events 
or death. We observe slight attenuation of the estimated treatment effects with recurrent 
event endpoints when taking the death as an additional event. This is to be expected given 
that the number of death events from both group are relatively small compared to 
hospitalization events and the treatment effect in time to death is not statistically significant 
with estimated hazard ratio of 0.88 (95% CI: 0.76 – 1.01, p=0.064). However, that all of 
the estimated rate ratio for the recurrent event endpoints of recurrent hospitalizations and 
death remain highly statistically significant.  
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In hierarchical endpoint analysis, the non-parametric approach based on 
generalized Gehan rank using pairwise comparison of composite endpoints in hierarchical 
manner also show statistically significant treatment benefit with win ratio indicating that 
more patients in the digoxin group had better outcome in longer survival or reduced risk to 
have hospitalization if death data is not available compared to the placebo group. The p 
values produced from the hierarchical endpoints analysis are similar to what obtained from 
Cox model for time to death or time to first hospitalization, indicating that by treating death 
in the first priority in the pairwise comparison and hospitalization events as the lower 
priority when death data is not applicable for pairwise comparison it did not reduce the 
efficiency in the DIG trial. This has been shown in the simulation study as well, when the 
effect size in both mortality rate and hospitalization event rate is similar, the hierarchical 
endpoint will be as efficient as conventional composite endpoint or have higher power. 
However, if the effect in reducing mortality is not significant at all, or hazard ratio is close 
to 1, the efficiency of using hierarchical endpoint will dramatically be reduced because by 
comparing death in the first priority will dilute the treatment benefit in reducing 
hospitalization events, which is lower priority in the hierarchy.  
In conclusion, we evaluated some alternative endpoints for evaluating treatment 
benefit of digoxin in chronic heart failure patients in DIG trial with its first year follow-up 
data. The results based on recurrent event models and hierarchical endpoint method showed 
the robust treatment benefit of digoxin in reducing recurrent hospitalization events or death 
compared to placebo. Although the time to first event including composite endpoint of time 
to death or time to first hospitalization is more appealing for its simplicity and familiarity, 
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we strongly feel in the future heart failure trials we should make the most of incorporating 
all hospitalizations (not just for first) into the primary endpoint with regard to treatment 
benefit.   
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Chapter 5 Evaluating Heart Failure Endpoints with Trials with Variable Follow-
up Time in the Simulation Study 
In Chapter 3 we evaluated the performance of various endpoints in assessing the 
treatment effect of the active drug versus control in the simulation studies whose the 
follow-up duration was fixed for all the patients. However, in most clinical studies, the 
patients were enrolled at different time, thus when the final database locked, patients will 
have different follow-up duration in the study. For example, some patients enrolled in the 
early portion of the study, theoretically they will have longer follow-up time compared to 
those enrolled in the later portion of study if the patients were not dead or loss-to-follow-
up. In this chapter we extended what have been done in Chapter 3 to examine what is the 
performance of each endpoint in the studies where the follow-up times were different for 
each patient. One major difference in this chapter compared to Chapter 3 (studies with 
fixed follow-up duration) is for hierarchical endpoints, the rest of endpoints were analyzed 
similarly although we will have more events due to the longer follow-up time compared to 
1 year fixed follow-up duration in Chapter 3. How to evaluate the second endpoint in the 
hierarchical endpoints where death information is not applicable to compare in the first 
hierarchy as the either time to first hospitalization or number of hospitalization need to be 
compared based on the shortest common duration between two patients. We will discuss 
the approach to dynamically compare the second endpoint in the hierarchical endpoints 
when the death event was not applicable to compare in this chapter and summarized the 
simulation results.  
104 
 
 
 
 
5.1 The Simulation Process  
We used the same simulation process as described in the Chapter 3 to simulate the 
death and hospitalization events. Weibull distribution with shape parameter=1 was used to 
simulate time to death data, see Equation 5.1, and Poisson process was used to simulate 
hospitalization gap times, see Equation 5.2.  
𝑡𝑖𝑗 = −
log(𝑈𝑖𝑗)
− log(1 − 𝑝𝑖)
, 𝑖 = 1, 2, 𝑗 = 1,… , 𝑛, 𝑈𝑖𝑗~𝑈(0,1)                          (5.1) 
      𝑦𝑖𝑗𝑘 = − log(𝑈𝑖𝑗𝑘) /𝑢𝑖; 𝑖 = 1, 2, 𝑗 = 1,… , 𝑛, 𝑘 = 1, . . , 𝐾, 𝑈𝑖𝑗𝑘~𝑈(0,1)                 (5.2)  
Where 𝑡𝑖𝑗is time to death for subject j in treatment group 𝑖,   𝑝𝑖 is the 1 year mortality rate 
in group 𝑖, 𝑈𝑖𝑗 is uniform (0,1) random variable; 𝑦𝑖𝑗𝑘 is the hospitalization gap time for 
subject j for event k in treatment group 𝑖, 𝑢𝑖 is the mean hospitalization rate per year for 
group 𝑖, 𝑈𝑖𝑗𝑘 is uniform (0,1) random variable. To account for the censoring at last follow-
up in the study, the censoring time  
𝐶𝑖𝑗 was introduced for each patient, where 𝐶𝑖𝑗 is uniform (0, 4.8) random variable. If 𝑡𝑖𝑗 ≤
𝐶𝑖𝑗, it was considered as the death event at 𝑡𝑖𝑗, and if  𝑡𝑖𝑗 > 𝐶𝑖𝑗 then the death was censored 
at time 𝐶𝑖𝑗. As for the total numbers of hospitalizations for each patient, it was determined 
as following: 
𝑁𝐻𝑂𝑆𝑃𝑖𝑗 =
{
  
 
  
 
 
0,                                   𝑖𝑓 𝑦𝑖𝑗1 > 𝑡𝑖𝑗
1,                 𝑖𝑓𝑦𝑖𝑗1 < 𝑡𝑖𝑗 <∑𝑦𝑖𝑗𝑘
2
𝑘=1
𝑘 − 1,      𝑖𝑓 ∑𝑦𝑖𝑗𝑘
𝑘−1
𝑘=1
< 𝑡𝑖𝑗 <∑𝑦𝑖𝑗𝑘
𝑘
𝑘=1
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And the time to each hospitalization is denoted by ∑ 𝑦𝑖𝑗𝑘
𝑘
𝑘=1 . For patient with no 
hospitalization event, time to hospitalization would be censored at 𝑡𝑖𝑗.  
Four groups of simulations were performed: 
1. No treatment effect in both time to death and time to hospitalization  
This simulation will be used to assess the false positive rate (type 1 error) of each 
statistical method for analyzing different type of endpoints. In this group of simulations 
the treatment effect was set to zero, that is, 1 year mortality rate and mean 
hospitalization event rate is equal for both treatment group.  
2. The equal effect size in both time to death and time to hospitalization 
Simulations were performed to assess the power and performance of each statistical 
test and different endpoint when the treatment benefit in both mortality rate and mean 
hospitalization event is the same.  
3. The effect size in time to death larger than mean hospitalization event rate  
Simulations were performed to assess the power and performance of each statistical 
test and different endpoint when the treatment benefit in reducing mortality rate is 
larger than that reducing mean hospitalization event rate.  
4. The effect size in reducing hospitalization rate is larger than reducing mortality rate   
Simulations were performed to assess the power and performance of each statistical 
test and different endpoint when the treatment benefit in reducing mortality rate is 
smaller than that reducing mean hospitalization event rate.  
5.2 Generating the Time to Death and Recurrent Hospitalization Event Data  
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There were 20,000 replicates of each simulation performed for the false positive 
rate analysis and 5,000 replicates of each simulation for the power analysis. The 
individual replicates contained the number of subjects in the control and treatment 
groups, n =100, 150, 200, 250, and 500 per group. The mortality rate and mean 
hospitalization rate used in each group of simulations were listed in Table 28.  
                             Table 28: Treatment Effect Size Used in Simulation  
Simulation group 1 year mortality rate Mean Hospitalization Rate 
𝑝 𝑢 
1. No Treatment Effect 
Control 0.15 0.75 
Treatment 0.15 0.75 
2. Equal Treatment Effect in Both Mortality and Hospitalization Events (20% 
reduction) 
Control 0.15 0.75 
Treatment 0.12 0.60 
3a. Unequal Treatment Effect in Both Mortality and Hospitalization Events (Effect in 
reducing Mortality > Effect in reducing Hospitalization rate) 
Control 0.15 0.75 
Treatment 0.10 0.60 
3b. Unequal Treatment Effect in Both Mortality and Hospitalization Events (Effect in 
reducing Mortality < Effect in reducing Hospitalization) 
Control 0.15 0.75 
Treatment 0.12 0.45 
 
We will evaluate following total 14 type of approaches, see Table 29. The first 3 
endpoints (time to single event type endpoint) will be analyzed by standard Cox model. 
The next 5 recurrent event including death will be analyzed using method extended 
from Cox model see details in Chapter 2. The 9th and 10th approaches are based on 
Poisson model and negative binomial model to evaluate the event count. The last 4 
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endpoints are hierarchical endpoints.  The hierarchical endpoints will be analyzed using 
generalized Gehan-Wilcoxon test via pair-wise comparison between patients. The test 
statistics is based on Gehan rank.  In Table 29, it described the details of the endpoints 
and statistical methods for analyzing the data. 
Table 29: Endpoint and Statistical Method for Analysis 
Index Endpoint Statistical Method 
1 Time to Death Cox Model 
2 Time to First Hospitalization Cox Model 
3 Time to Death or Time to First Hospitalization  Cox Model 
4 Recurrent hospitalization or death AG model 
5 Recurrent hospitalization or death WLW model 
6 Recurrent hospitalization or death PWPa model 
7 Recurrent hospitalization or death PWP gap time model 
8 Recurrent hospitalization or death Multistate model 
9 Recurrent hospitalization or death event Poisson Model  
10 Recurrent hospitalization or death event  Negative Binomial Model 
11 
Hierarchical endpoint with death as first priority, 
followed with number of hospitalization  
Pairwise Comparison with 
Generalized Gehan-
Wilcoxon test 
12 
Hierarchical endpoint with death as first priority, 
followed with time to first hospitalization  
Pairwise Comparison with 
Generalized Gehan-
Wilcoxon test 
13 
Hierarchical endpoint with death as first priority, 
followed with number of hospitalization, 
followed with time to first hospitalization 
Pairwise Comparison with 
Generalized Gehan-
Wilcoxon test 
14 
Hierarchical endpoint with death as first priority, 
followed with time to first hospitalization, 
followed with number of hospitalization  
Pairwise Comparison with 
Generalized Gehan-
Wilcoxon test 
 
5.3 Adjustment in Hierarchical Endpoint Evaluation Algorithm 
Because hierarchical endpoints were evaluated in hierarchical order, with death event 
evaluated at first priority, when the death events were not applicable for determine which 
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patient had better outcome, then resorted to the secondary hierarchical endpoint. Because 
each patients were followed with different durations in the study, it would not be fair to 
compare the number of hospitalizations at their own length of follow-up as the number of 
hospitalizations would be confounded by the length of follow-up, usually the longer in the 
follow-up, the higher chance to observe more events. In order to have fair comparison on 
the secondary hierarchical endpoint when the first hierarchical endpoint comparison was 
deemed non-informative, we have to dynamically compare the number of hospitalizations 
or time to first hospitalizations based on the shortest common length of follow-up. 
Following steps were taken to capture the number of hospitalizations or time to first 
hospitalization in the shortest common length of follow-up in pairwise comparison for 
hierarchical endpoints analysis. 
1. Obtain the minimum value of shortest follow-up by comparing two death events, 
denoted as minsurv 
2. Calculate number of hospitalizations for each patient in the pairwise comparison 
using following rule: 
𝑁𝑢𝐻𝑂𝑆𝑃𝑖𝑗 =
{
  
 
  
 
 
0,                                   𝑖𝑓 𝑦𝑖𝑗1 > 𝑚𝑖𝑛𝑠𝑢𝑟𝑣
1,                 𝑖𝑓𝑦𝑖𝑗1 < 𝑚𝑖𝑛𝑠𝑢𝑟𝑣 < ∑𝑦𝑖𝑗𝑘
2
𝑘=1
𝑘 − 1,      𝑖𝑓 ∑𝑦𝑖𝑗𝑘
𝑘−1
𝑘=1
< 𝑚𝑖𝑛𝑠𝑢𝑟𝑣 < ∑𝑦𝑖𝑗𝑘
𝑘
𝑘=1
 
3. Resign the censoring status and calculate time to first hospitalization by comparing 
𝑦𝑖𝑗1  to minsurv. If 𝑦𝑖𝑗1 ≤ 𝑚𝑖𝑛𝑠𝑢𝑟𝑣 , no change needed, otherwise, if 𝑦𝑖𝑗1 >
𝑚𝑖𝑛𝑠𝑢𝑟𝑣, then time to first hospitalization was censored at minsurv.  
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5.4 The Simulation Results 
5.4.1 No treatment effect group of simulation (false positive rate) 
The results for the no treatment effect group of simulations where the treatment 
effect was set to zero are shown in the Table 30. The aim of performing this group of 
simulations was to assess any form of bias in the simulation process. As all the HRs 
approximately equaled to 1 in the Cox model or recurrent event models when sample size 
increases to 250/group or higher, indicating that the bias was reduce to zero when sample 
size increases. As the treatment effect was set to zero in both mortality and hospitalization 
event rate that roughly 5% of the replicates would show a significant effect for both the 
control and the treatment group. This was reflected in the percentage of replicates that were 
significant in 20000 simulations, see Figure 12. All the approaches except for the Poisson 
model had the false positive rate around 5%, while Poisson model had higher false positive 
rate. The reason for Poisson model for event rate might be explained by the violation of 
constant event rate over time and the different duration of follow-up for each patient in this 
set of simulation.  
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 Figure 12: Percent of Replicates with Significant P values 
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Table 30: Results for the no treatment effect simulations 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=100/group Time to death, Cox Model 1.03 (0.004) 0.05 
Time to first hospitalization, Cox Model 1.02 (0.003) 0.059 
Time to death or first hospitalization, Cox Model 1.01 (0.002) 0.0542 
Recurrent hospitalization or death - AG model 1 (0.002) 0.0568 
Recurrent hospitalization or death - WLW model 1.02 (0.003) 0.0636 
Recurrent hospitalization or death - PWPa model 1 (0.002) 0.0516 
Recurrent hospitalization or death - PWPb model 1.01 (0.002) 0.055 
Recurrent hospitalization or death - Multistate model 1 (0.002) 0.0516 
Hospitalization or death event - Poisson model  0.095 
Hospitalization or death event - Negative binomial model  0.05 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.036 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.053 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.046 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.053 
    
N=150/group Time to death, Cox Model 1.02 (0.003) 0.0506 
Time to first hospitalization, Cox Model 1.01 (0.002) 0.0488 
Time to death or first hospitalization, Cox Model 1.01 (0.002) 0.0454 
Recurrent hospitalization or death - AG model 1 (0.001) 0.052 
Recurrent hospitalization or death - WLW model 1.01 (0.002) 0.0532 
Recurrent hospitalization or death - PWPa model 1.01 (0.001) 0.055 
Recurrent hospitalization or death - PWPb model 1.01 (0.001) 0.0524 
Recurrent hospitalization or death - Multistate model 1.01 (0.001) 0.0538 
Hospitalization or death event - Poisson model  0.0902 
Hospitalization or death event - Negative binomial model  0.0458 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.046 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.04 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.039 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.040 
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Table 30: Results for the no treatment effect simulations 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=200/group Time to death, Cox Model 1.02 (0.003) 0.0482 
Time to first hospitalization, Cox Model 1.01 (0.002) 0.053 
Time to death or first hospitalization, Cox Model 1.01 (0.002) 0.0566 
Recurrent hospitalization or death - AG model 1 (0.001) 0.0536 
Recurrent hospitalization or death - WLW model 1.01 (0.002) 0.0562 
Recurrent hospitalization or death - PWPa model 1 (0.001) 0.0516 
Recurrent hospitalization or death - PWPb model 1 (0.001) 0.0536 
Recurrent hospitalization or death - Multistate model 1 (0.001) 0.0512 
Hospitalization or death event - Poisson model  0.0964 
Hospitalization or death event - Negative binomial model  0.0532 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.047 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.054 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.052 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.054 
    
N=250/group Time to death, Cox Model 1.01 (0.002) 0.0482 
Time to first hospitalization, Cox Model 1.01 (0.002) 0.0482 
Time to death or first hospitalization, Cox Model 1.01 (0.001) 0.0488 
Recurrent hospitalization or death - AG model 1 (0.001) 0.0524 
Recurrent hospitalization or death - WLW model 1.01 (0.002) 0.0506 
Recurrent hospitalization or death - PWPa model 1 (0.001) 0.0502 
Recurrent hospitalization or death - PWPb model 1 (0.001) 0.0502 
Recurrent hospitalization or death - Multistate model 1 (0.001) 0.0496 
Hospitalization or death event - Poisson model  0.0986 
Hospitalization or death event - Negative binomial model  0.0532 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.054 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.051 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.047 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.051 
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Table 30: Results for the no treatment effect simulations 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=500/group Time to death, Cox Model 1.01 (0.002) 0.0476 
Time to first hospitalization, Cox Model 1 (0.001) 0.0452 
Time to death or first hospitalization, Cox Model 1 (0.001) 0.046 
Recurrent hospitalization or death - AG model 1 (0.001) 0.0502 
Recurrent hospitalization or death - WLW model 1 (0.001) 0.0466 
Recurrent hospitalization or death - PWPa model 1 (0.001) 0.0508 
Recurrent hospitalization or death - PWPb model 1 (0.001) 0.0512 
Recurrent hospitalization or death - Multistate model 1 (0.001) 0.0504 
Hospitalization or death event - Poisson model  0.0976 
Hospitalization or death event - Negative binomial model  0.0506 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.046 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.039 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.044 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.039 
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5.4.2   The equal treatment effect in mortality rate and hospitalization event rate 
The results for the equal treatment effect in both mortality and hospitalization event 
is shown in the Table 31. In this simulation, treatment group has 20% improvement in 
reducing mortality and mean hospitalization event rate. The control group has the same 
estimates as used in no effect simulation, 1 year mortality rate=0.15 and mean 
hospitalization event=0.75, while treatment group with 1 year mortality rate of 0.12 and 
mean hospitalization event rate=0.60. Comparing to the simulation results in 1 year follow-
up study, the estimates of HR for time to death or time to first hospitalization were more 
precise in the study with variable follow-up duration, as it increased the event numbers 
from both death counts and hospitalization event counts. As for HRs estimated for time to 
first hospitalization, time to mortality or time to first hospitalization, and recurrent 
hospitalization events or death, most methods gave the expected results (that is HR=0.80) 
whereas the WLW model overestimates the treatment effect with HR around 0.73-0.75.  
Figure 13 displayed the percentage of replicates with significant p-values by different 
methods. It is true when the sample size the percentage of replicates with significant p-
value increases in all the studied methods. Because small mortality rate and expected 
HR=0.8, the power to detect treatment benefit in mortality increased from 14% to 52% for 
sample size of 100 to 500 per group, respectively, which was larger than what was observed 
from Chapter 3  with 1 year fixed follow-up under same assumption criteria. Using the 
composite endpoint of time to death or time to first hospitalization, it increased the number 
of events for the analysis, thus the power is larger than that obtained in the individual 
endpoint analysis, time to death only or time to first hospitalization, with power ranging 
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from 29% to 87% with sample size 100 to 500 per group, respectively. The recurrent event 
models achieved the highest power compared to event count models and hierarchical 
endpoints approaches. Among recurrent event model, WLW model overestimated the 
treatment effect, but the power was relatively smaller compared to AG model, PWP models, 
and multi-state model. Among 4 hierarchical models, one with three hierarchical 
components (first with death, second with time to first hospitalization, and final with 
number of hospitalizations) had the highest power compared the rest three. This 
hierarchical endpoint had slightly higher or similar  power compared to composite endpoint 
of time to death or time to first hospitalization, with 29%, 41%, 50%, 58%, and 88% with 
sample size of 100, 150, 200, 250, and 500 per group, respectively in hierarchical endpoint, 
while 29%, 39%, 49%, 58%, and 87% with sample size of 100, 150, 200, 250, and 500 per 
group, respectively in composite endpoint. Both hierarchical endpoints with two 
components had lower power compared to the composite endpoint approach, with 
hierarchical endpoint of death and number of hospitalization performed better than 
hierarchical endpoint of death and time to first to hospitalization. With the same effect size 
in both mortality rate and hospitalization event rate and larger event rate in hospitalization 
events, during the variable follow-up design, more hospitalization events were observed 
than death events, thus with composite endpoint of death or time to first hospitalization had 
more hospitalization events counted as the endpoint compared to in two component of 
hierarchical endpoint as the less events from hospitalization were counted as the endpoint 
to be compared. With three components of hierarchical endpoints, although the death 
events were counted first, and more hospitalization information was used to compare 
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between pair-wise comparisons, thus it increased the power. The power results from the 
simulation study with the variable follow-up design were always higher compared to the 
same simulation performed in the 1 year fixed duration design summarized in the Section 
3.3 in Chapter 3, because with variable follow-up design, it increased the number of death 
events and hospitalization events.  
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Figure 13: Percent of replicates with significant pvalue with equal treatment effect in both mortality 
and mean hospitalization rate. 
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Table 31: Results for the equal treatment effect in mortality and hospitalization rate simulations 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=100/group Time to death, Cox Model 0.81 (0.005) 0.142 
Time to first hospitalization, Cox Model 0.81 (0.003) 0.2295 
Time to death or first hospitalization, Cox Model 0.8 (0.003) 0.286 
Recurrent hospitalization or death - AG model 0.8 (0.002) 0.521 
Recurrent hospitalization or death - WLW model 0.74 (0.003) 0.399 
Recurrent hospitalization or death - PWPa model 0.8 (0.002) 0.4945 
Recurrent hospitalization or death - PWPb model 0.8 (0.002) 0.483 
Recurrent hospitalization or death - Multistate model 0.8 (0.002) 0.4945 
Hospitalization or death event - Poisson model  0.378 
Hospitalization or death event - Negative binomial model  0.2935 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.195 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.259 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.288 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.259 
    
N=150/group Time to death, Cox Model 0.8 (0.003) 0.203 
Time to first hospitalization, Cox Model 0.82 (0.002) 0.3275 
Time to death or first hospitalization, Cox Model 0.81 (0.002) 0.3945 
Recurrent hospitalization or death - AG model 0.82 (0.001) 0.6815 
Recurrent hospitalization or death - WLW model 0.75 (0.002) 0.5335 
Recurrent hospitalization or death - PWPa model 0.81 (0.001) 0.6535 
Recurrent hospitalization or death - PWPb model 0.81 (0.001) 0.6645 
Recurrent hospitalization or death - Multistate model 0.81 (0.001) 0.6615 
Hospitalization or death event - Poisson model  0.4795 
Hospitalization or death event - Negative binomial model  0.373 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.289 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.384 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.412 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.384 
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Table 31: Results for the equal treatment effect in mortality and hospitalization rate simulations 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
  
N=200/group Time to death, Cox Model 0.8 (0.003) 0.24 
Time to first hospitalization, Cox Model 0.81 (0.002) 0.4065 
Time to death or first hospitalization, Cox Model 0.8 (0.002) 0.4855 
Recurrent hospitalization or death - AG model 0.8 (0.001) 0.7915 
Recurrent hospitalization or death - WLW model 0.74 (0.002) 0.6425 
Recurrent hospitalization or death - PWPa model 0.8 (0.001) 0.777 
Recurrent hospitalization or death - PWPb model 0.8 (0.001) 0.781 
Recurrent hospitalization or death - Multistate model 0.8 (0.001) 0.7785 
Hospitalization or death event - Poisson model  0.594 
Hospitalization or death event - Negative binomial model  0.488 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.353 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.448 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.499 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.448 
    
N=250/group Time to death, Cox Model 0.8 (0.003) 0.285 
Time to first hospitalization, Cox Model 0.81 (0.002) 0.483 
Time to death or first hospitalization, Cox Model 0.8 (0.002) 0.5815 
Recurrent hospitalization or death - AG model 0.8 (0.001) 0.8765 
Recurrent hospitalization or death - WLW model 0.74 (0.002) 0.7465 
Recurrent hospitalization or death - PWPa model 0.8 (0.001) 0.8655 
Recurrent hospitalization or death - PWPb model 0.8 (0.001) 0.8685 
Recurrent hospitalization or death - Multistate model 0.8 (0.001) 0.8645 
Hospitalization or death event - Poisson model  0.6675 
Hospitalization or death event - Negative binomial model  0.5675 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.391 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.524 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.582 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.524 
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Table 31: Results for the equal treatment effect in mortality and hospitalization rate simulations 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=500/group Time to death, Cox Model 0.79 (0.002) 0.5175 
Time to first hospitalization, Cox Model 0.8 (0.001) 0.787 
Time to death or first hospitalization, Cox Model 0.8 (0.001) 0.868 
Recurrent hospitalization or death - AG model 0.8 (0.001) 0.9955 
Recurrent hospitalization or death - WLW model 0.73 (0.001) 0.964 
Recurrent hospitalization or death - PWPa model 0.8 (0.001) 0.994 
Recurrent hospitalization or death - PWPb model 0.8 (0.001) 0.9945 
Recurrent hospitalization or death - Multistate model 0.8 (0.001) 0.9945 
Hospitalization or death event - Poisson model  0.9105 
Hospitalization or death event - Negative binomial model  0.861 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.687 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.831 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.879 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.831 
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5.4.3 The unequal treatment effect with larger effect in mortality rate than that in 
hospitalization event rate 
The results for the unequal treatment effect with larger treatment effect in reducing 
mortality than that in reducing mean hospitalization rate is shown in the Table 32. In this 
simulation, treatment group has 33% improvement in reducing mortality and 20% 
reduction in mean hospitalization event rate. The control group has the same estimates as 
used in no effect simulation, 1 year mortality rate=0.15 and mean hospitalization 
event=0.75, while treatment group with 1 year mortality rate of 0.10 and mean 
hospitalization event rate=0.60. The estimated HR of time to death is closed to what used 
in the simulation when sample size increases to 400 and 500. As for HRs estimated for 
time to first hospitalization, time to mortality or time to first hospitalization, and recurrent 
hospitalization events or death, most methods gave the expected results whereas the WLW 
model overestimates the treatment effect.  Figure 14 displayed the percentage of replicates 
with significant p-values by different methods. It is true when the sample size the 
percentage of replicates with significant p-value increases in all the evaluated methods. 
Using the composite endpoint of time to death or time to first hospitalization when effect 
in mortality is larger than time to first hospitalization, the absolute power increases 
compared to each individual endpoint is much higher than what observed under the 
condition whether the effect size was same for both time to death and time to first 
hospitalization. The recurrent event models had the highest power among all the methods 
evaluated, and among those recurrent event models, WLW had lowest power with 
overestimated HR. The all four hierarchical endpoint approaches displayed higher power 
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compared to composite endpoint approach, with three components hierarchical endpoint 
of death, time to first hospitalization and number of hospitalization achieved the highest 
power among 4 hierarchical endpoint approaches.   
              Figure 14: Percent of replicates with significant pvalue with larger treatment effect in 
mortality than in mean hospitalization rate. 
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Table 32: Results for the unequal treatment effect with larger effect in mortality 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=100/group Time to death, Cox Model 0.67 (0.003) 0.354 
Time to first hospitalization, Cox Model 0.82 (0.002) 0.2305 
Time to death or first hospitalization, Cox Model 0.79 (0.002) 0.3435 
Recurrent hospitalization or death - AG model 0.79 (0.001) 0.6335 
Recurrent hospitalization or death - WLW model 0.73 (0.002) 0.476 
Recurrent hospitalization or death - PWPa model 0.78 (0.001) 0.6045 
Recurrent hospitalization or death - PWPb model 0.78 (0.001) 0.612 
Recurrent hospitalization or death - Multistate model 0.78 (0.001) 0.609 
Hospitalization or death event - Poisson model  0.347 
Hospitalization or death event - Negative binomial model  0.265 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.378 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.415 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.447 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.415 
    
N=150/group Time to death, Cox Model 0.67 (0.002) 0.473 
Time to first hospitalization, Cox Model 0.82 (0.002) 0.3315 
Time to death or first hospitalization, Cox Model 0.79 (0.002) 0.4815 
Recurrent hospitalization or death - AG model 0.79 (0.001) 0.782 
Recurrent hospitalization or death - WLW model 0.73 (0.002) 0.625 
Recurrent hospitalization or death - PWPa model 0.78 (0.001) 0.7655 
Recurrent hospitalization or death - PWPb model 0.78 (0.001) 0.7615 
Recurrent hospitalization or death - Multistate model 0.78 (0.001) 0.7675 
Hospitalization or death event - Poisson model  0.49 
Hospitalization or death event - Negative binomial model  0.377 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.508 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.56 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.61 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.56 
N=200/group Time to death, Cox Model 0.66 (0.002) 0.5785 
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Table 32: Results for the unequal treatment effect with larger effect in mortality 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
Time to first hospitalization, Cox Model 0.82 (0.002) 0.4185 
Time to death or first hospitalization, Cox Model 0.79 (0.001) 0.61 
Recurrent hospitalization or death - AG model 0.79 (0.001) 0.8965 
Recurrent hospitalization or death - WLW model 0.73 (0.001) 0.747 
Recurrent hospitalization or death - PWPa model 0.78 (0.001) 0.8845 
Recurrent hospitalization or death - PWPb model 0.78 (0.001) 0.8885 
Recurrent hospitalization or death - Multistate model 0.78 (0.001) 0.8885 
Hospitalization or death event - Poisson model  0.5755 
Hospitalization or death event - Negative binomial model  0.4635 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.584 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.68 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.719 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.68 
    
N=250/group Time to death, Cox Model 0.66 (0.002) 0.6675 
Time to first hospitalization, Cox Model 0.82 (0.001) 0.4965 
Time to death or first hospitalization, Cox Model 0.78 (0.001) 0.6925 
Recurrent hospitalization or death - AG model 0.79 (0.001) 0.943 
Recurrent hospitalization or death - WLW model 0.72 (0.001) 0.821 
Recurrent hospitalization or death - PWPa model 0.78 (0.001) 0.9355 
Recurrent hospitalization or death - PWPb model 0.78 (0.001) 0.937 
Recurrent hospitalization or death - Multistate model 0.78 (0.001) 0.9375 
Hospitalization or death event - Poisson model  0.6605 
Hospitalization or death event - Negative binomial model  0.5605 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.714 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.76 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.804 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.76 
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Table 32: Results for the unequal treatment effect with larger effect in mortality 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=500/group Time to death, Cox Model 0.65 (0.002) 0.936 
Time to first hospitalization, Cox Model 0.8 (0.001) 0.8 
Time to death or first hospitalization, Cox Model 0.77 (0.001) 0.9405 
Recurrent hospitalization or death - AG model 0.78 (0.001) 0.999 
Recurrent hospitalization or death - WLW model 0.71 (0.001) 0.9825 
Recurrent hospitalization or death - PWPa model 0.77 (0.001) 0.999 
Recurrent hospitalization or death - PWPb model 0.77 (0.001) 0.9995 
Recurrent hospitalization or death - Multistate model 0.77 (0.001) 0.9995 
Hospitalization or death event - Poisson model  0.8985 
Hospitalization or death event - Negative binomial model  0.8475 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan test  0.971 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.974 
Hierarchical endpoint (death, t2first hosp, # of hosp)- Generalized 
Gehan test 
 0.984 
Hierarchical endpoint (death, # of hosp, t2first hosp) - Generalized 
Gehan test 
 0.974 
    
 
 
 
 
126 
 
 
 
 
5.4.4 The unequal treatment effect with larger effect in hospitalization rate than 
that in mortality rate 
The results for the unequal treatment effect with larger treatment effect in reducing 
hospitalization rate than that in reducing mortality rate is shown in the Table 33. In this 
simulation, treatment group has 20% improvement in reducing mortality and 40% 
reduction in mean hospitalization event rate. The control group has the same estimates as 
used in no effect simulation, 1 year mortality rate=0.15 and mean hospitalization 
event=0.75, while treatment group with 1 year mortality rate of 0.12 and mean 
hospitalization event rate=0.45. The power to detect time to death between groups is very 
low and similar to what observed in Section 5.4.2, where the effect size of mortality is the 
same as we simulated here. As for HRs estimated for time to first hospitalization, time to 
mortality or time to first hospitalization, and recurrent hospitalization events or death, most 
methods gave the expected results whereas the WLW model overestimates the treatment 
effect.  Figure 15 displayed the percentage of replicates with significant p-values by 
different methods. It is true when the sample size increase the percentage of replicates with 
significant p-value increases in all methods. Using the composite endpoint of time to death 
or time to first hospitalization when effect in mortality is smaller than time to first 
hospitalization, the absolute power increase compared to time to first hospitalization is 
relatively smaller as the majority of events in composite endpoint was attributed to time to 
first hospitalization event. Furthermore, the hierarchical endpoint approaches had less 
power compared to what obtained in the composite endpoint approach. In addition, the 
power for the hierarchical endpoint of death and time to first hospitalization was smallest 
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among 4 hierarchical endpoints. The reason can be explained by the algorithm in the 
hierarchical endpoint pairwise comparison where the death events were compared first 
even more treatment effect was assumed in hospitalization event rate. Thus the impact of 
time to first hospitalization was not well appreciated in this situation while the rest three 
hierarchical endpoints still benefit from the comparison based on the total number of 
hospitalizations.  
Figure 15: Percent of replicates with significant pvalue with larger treatment effect in hospitalization 
rate than in mortality rate  
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Table 33: Results for the unequal treatment effect with larger effect in hospitalization 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=100/group Time to death, Cox Model 0.82 (0.005) 0.145 
Time to first hospitalization, Cox Model 0.61 (0.003) 0.7655 
Time to death or first hospitalization, Cox Model 0.64 (0.002) 0.776 
Recurrent hospitalization or death - AG model 0.64 (0.002) 0.9635 
Recurrent hospitalization or death - WLW model 0.53 (0.002) 0.9235 
Recurrent hospitalization or death - PWPa model 0.64 (0.002) 0.9565 
Recurrent hospitalization or death - PWPb model 0.64 (0.002) 0.959 
Recurrent hospitalization or death - Multistate model 0.64 (0.002) 0.9545 
Hospitalization or death event - Poisson model  0.8975 
Hospitalization or death event - Negative binomial model  0.8615 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan 
test 
 0.322 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.573 
Hierarchical endpoint (death, t2first hosp, # of hosp)- 
Generalized Gehan test 
 0.633 
Hierarchical endpoint (death, # of hosp, t2first hosp) - 
Generalized Gehan test 
 0.573 
    N=150/group Time to death, Cox Model 0.81 (0.004) 0.191 
Time to first hospitalization, Cox Model 0.61 (0.002) 0.914 
Time to death or first hospitalization, Cox Model 0.64 (0.002) 0.91 
Recurrent hospitalization or death - AG model 0.64 (0.001) 0.9935 
Recurrent hospitalization or death - WLW model 0.53 (0.002) 0.98 
Recurrent hospitalization or death - PWPa model 0.64 (0.001) 0.993 
Recurrent hospitalization or death - PWPb model 0.64 (0.001) 0.993 
Recurrent hospitalization or death - Multistate model 0.64 (0.001) 0.992 
Hospitalization or death event - Poisson model  0.972 
Hospitalization or death event - Negative binomial model  0.957 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan 
test 
 0.448 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.734 
Hierarchical endpoint (death, t2first hosp, # of hosp)- 
Generalized Gehan test 
 0.793 
Hierarchical endpoint (death, # of hosp, t2first hosp) - 
Generalized Gehan test 
 
 0.734 
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Table 33: Results for the unequal treatment effect with larger effect in hospitalization 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=200/group Time to death, Cox Model 0.8 (0.003) 0.237 
Time to first hospitalization, Cox Model 0.6 (0.002) 0.973 
Time to death or first hospitalization, Cox Model 0.64 (0.002) 0.976 
Recurrent hospitalization or death - AG model 0.64 (0.001) 0.9995 
Recurrent hospitalization or death - WLW model 0.52 (0.002) 0.998 
Recurrent hospitalization or death - PWPa model 0.63 (0.001) 0.9995 
Recurrent hospitalization or death - PWPb model 0.63 (0.001) 0.9995 
Recurrent hospitalization or death - Multistate model 0.63 (0.001) 0.9995 
Hospitalization or death event - Poisson model  0.996 
Hospitalization or death event - Negative binomial model  0.9915 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan 
test 
 0.579 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.849 
Hierarchical endpoint (death, t2first hosp, # of hosp)- 
Generalized Gehan test 
 0.893 
Hierarchical endpoint (death, # of hosp, t2first hosp) - 
Generalized Gehan test 
 0.849 
    
N=250/group Time to death, Cox Model 0.79 (0.003) 0.296 
Time to first hospitalization, Cox Model 0.6 (0.002) 0.992 
Time to death or first hospitalization, Cox Model 0.63 (0.002) 0.9895 
Recurrent hospitalization or death - AG model 0.64 (0.001) 1 
Recurrent hospitalization or death - WLW model 0.52 (0.001) 1 
Recurrent hospitalization or death - PWPa model 0.63 (0.001) 1 
Recurrent hospitalization or death - PWPb model 0.63 (0.001) 1 
Recurrent hospitalization or death - Multistate model 0.63 (0.001) 1 
Hospitalization or death event - Poisson model  1 
Hospitalization or death event - Negative binomial model  0.9975 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan 
test 
 0.681 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.937 
Hierarchical endpoint (death, t2first hosp, # of hosp)- 
Generalized Gehan test 
 0.961 
Hierarchical endpoint (death, # of hosp, t2first hosp) - 
Generalized Gehan test 
 0.937 
130 
 
 
 
 
 
Table 33: Results for the unequal treatment effect with larger effect in hospitalization 
 
 
Conditions Endpoint – Method 
Hazard 
Ratio(se) 
Percent 
Significant 
Replicates 
N=500/group Time to death, Cox Model 0.79 (0.002) 0.534 
Time to first hospitalization, Cox Model 0.6 (0.001) 1 
Time to death or first hospitalization, Cox Model 0.64 (0.001) 1 
Recurrent hospitalization or death - AG model 0.64 (0.001) 1 
Recurrent hospitalization or death - WLW model 0.52 (0.001) 1 
Recurrent hospitalization or death - PWPa model 0.63 (0.001) 1 
Recurrent hospitalization or death - PWPb model 0.63 (0.001) 1 
Recurrent hospitalization or death - Multistate model 0.63 (0.001) 1 
Hospitalization or death event - Poisson model  1 
Hospitalization or death event - Negative binomial model  1 
Hierarchical endpoint (death, t2first hosp) - Generalized Gehan 
test 
 0.937 
Hierarchical endpoint (death, # of hosp) - Generalized Gehan test  0.999 
Hierarchical endpoint (death, t2first hosp, # of hosp)- 
Generalized Gehan test 
 1 
Hierarchical endpoint (death, # of hosp, t2first hosp) - 
Generalized Gehan test 
 0.999 
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5.5 Summary 
In this Chapter, we evaluated the performance of 14 approaches in the heart failure 
trials with different follow-up time for each patient. From the results of the no treatment 
effect group of simulations it was seen that the simulation process was unbiased except for 
the regular Poisson model. All studied approaches achieved robust false positive rate 
around 5%.  
In general, the recurrent event model had higher power to detect treatment benefit 
compared to individual endpoint, composite endpoint, and hierarchical endpoint because 
in those models they used all recurrent hospitalization events and death events. When 
treatment benefit in mortality is larger than in reducing hospitalization rate, the all 
hierarchical endpoint approaches achieved higher power than composite endpoint, and 
when under the situation of equal treatment effect in mortality and hospitalization rate, the 
hierarchical endpoints had slightly higher power or equal power compared to composite 
endpoint approach. The reason is that death event is first component to differentiate 
treatment effect in pairwise comparison before hospitalization information was used for 
comparison. When the effect size of mortality rate is smaller than the treatment effect in 
hospitalization events, the power with hierarchical endpoints was smaller than the power 
observed from the composite endpoint approach.   
132 
 
 
 
Chapter 6 Evaluating HF Endpoints in the DIG Trial with Variable Follow-up 
In this chapter we will evaluate the efficiency of comparing the treatment benefit 
of Digoxin using different type of endpoints compared to composite endpoint of time to 
death or time to first hospitalization. The difference between what was summarized in this 
chapter compared to Chapter 4 is the follow-up duration. In the hierarchical endpoints 
evaluations, the revised algorithm based on the shortest common duration of follow-up in 
each pairwise comparison was applied.  
6.1 Methods  
6.1.1 Study design and patients 
The Digoxin Investigation Group (DIG) Trial was a randomized, double-blind, 
multicenter trial with more than 300 centers in the United States and Canada participating. 
The purpose of the trial was to examine the safety and efficacy of Digoxin in treating 
patients with congestive heart failure in sinus rhythm. In the main DIG trial, 6800 
ambulatory patients with chronic heart failure (ejection fraction <=45%) in normal sinus 
rhythm were randomized to receive digoxin or placebo during 1991-1993 and were 
followed for an average of 37 months. The primary outcome in the main DIG trial was all-
cause mortality. For the current analysis we evaluated following endpoints: all-cause 
mortality, time to first hospitalization, time to death or time to first to first hospitalization, 
death or recurrent hospitalization with different recurrent event models, death or recurrent 
hospitalization events with Poisson or negative binomial model, hierarchical endpoints 
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with mortality as first priority then followed with time to first hospitalization or number of 
hospitalization using generalized Gehan-Wilcoxon test.  
6.2 Results: 
Mortality and Frequency of Hospitalization during Long-term Follow-up 
The number of death and frequencies of hospitalization are presented in Table 34.  
Of the 6800 patients with chronic heart failure randomized, 1194 (35.1%) and 1181 (34.8%) 
deaths were observed in placebo and digoxin group, respectively during the study. The 
number of death events and hospitalization events were much higher than what observed 
in one-year DIG study displayed in Chapter 4. 
Table 34: Frequency of Death and Hospitalization during First Year Follow-up 
 Digoxin (N=3397) Placebo (N=3403) 
Number of death 1181 (34.8%) 1194 (35.1%) 
Number of hospitalizations   
                     0 1210 (35.6%) 1116 (32.8%) 
                     1 792 (23.3%) 809 (23.8%) 
                     2 506 (14.9%) 541 (15.9%) 
                     3 305 (9.0%) 292 (8.6%) 
                     4 194 (5.7%) 210 (6.2%) 
                     5 139 (4.1%) 138 (4.1%) 
                     6 69 (2.0%) 99 (2.9%) 
                     7 52 (1.5%) 55 (1.6) 
                    >=8    130 (3.9) 143 (4.3) 
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Figure 16: Frequency of Hospitalizations By Treatment 
 
 
Figure 17 shows the KM curve of overall survival by treatment group. Table 35 
displayed the log-rank test and Cox model results for comparing all-cause mortality 
between two groups in the long-term follow-up study. The log-rank p-value is 0.8011 and 
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hazard ratio is 0.99 (95% CI: 0.913 – 1.073). The results indicated that there is no 
statistically difference in overall survival benefit between two treatment groups.  
Table 35: Time to Death at the end of one year follow-up by treatment group 
 Placebo 
(N=3403) 
Digoxin 
(N=3397) 
Patients Censored n(%) 2209 (64.9) 2216 (65.2) 
Log-Rank p-value 0.8011  
HR (95% CI) 0.990 (0.913, 1.073)  
 
Figure 17: KM Curve of Overall Survival by treatment group 
 
The frequencies of hospitalizations are presented in Table 34. Of the 6800 patients 
randomized, 1348 (39.9%) and 1226 (43.9%) had at least one hospitalization during first 
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year of the study, in placebo and digoxin group, respectively. Because of many patients 
had more than 6 recurrent hospitalization events, in order to account for those data, we 
restricted the recurrent event analysis up to the 6th hospitalization. The result of time to 
first hospitalization was shown in Table 36.   
Table 36: Summary of Time to First Hospitalization by treatment group 
 Placebo 
(N=3403) 
Digoxin 
(N=3397) 
Patients Censored n(%) 1116 (32.8) 1210 (35.6) 
Log-Rank p-value 0.0052  
HR (95% CI) 0.920 (0.867, 0.975)  
 
The results indicated there is statistically significant difference in reducing time to 
first hospitalization, however the effect size is relatively small, HR=0.92 (95% CI: 0.87 – 
0.98, p=0.0052). Figure 18 shows the KM curve for time to first hospitalization between 
two groups. 
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Figure 18: KM curve for time to first hospitalization between two groups. 
 
Composite Endpoint: time to death or time to first hospitalization 
The Table 37 shows the results from log-rank test and cox model for comparing 
two groups using composite endpoint, time to death or time to first hospitalization. With 
composite endpoints, there are 2652 (75%) and 2506 (73.8%) events in digoxin and 
placebo group, respectively.  
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Table 37: Time to Death or time to First Hospitalization by treatment group 
 Placebo 
(N=3403) 
Digoxin 
(N=3397) 
Patients Censored n(%) 851 (25.0) 891 (26.2) 
Log-Rank p-value 0.0424  
HR (95% CI) 0.945 (0.894, 0.998)  
 
Compared to time to first hospitalization event only, using the composite endpoint, 
it increased the number of events slightly as the death event was small in both groups in 
overall, however the log-rank test was less significant and Hazard ratio was relatively 
smaller than that observed in time to first hospitalization analysis.  The Figure 19 shows 
the KM curve by treatment group for the composite endpoint. 
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Figure 19: KM curve for time to death or time to first hospitalization between two groups.  
 
 
Recurrent hospitalizations or death event analysis 
The results for the four recurrent event models and one multistate model as well as 
the time to first event Cox models are shown in Table 38. 
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Table 38: The time-to-first event Cox model and recurrent event analyses based on the first 4 
hospitalizations or death in the DIG trial. 
Model Hazard ratio, 
95% CI 
P-value 
Time to death – Cox model 0.99 (0.91, 1.07) 0.8011 
Time to first hospitalization – Cox model 0.92 (0.87, 0.98) 0.0052 
Time to death or time to first hospitalization – Cox 
model 
0.95 (0.89, 0.998) 0.0424 
Recurrent hospitalizations or death – AG model 0.94 (0.90, 0.99) 0.0283 
Recurrent hospitalizations or death – WLW model 0.92 (0.86, 0.98) 0.0134 
Recurrent hospitalizations or death – PWPa model 0.98 (0.95, 1.02) 0.274 
Recurrent hospitalizations or death – PWPb model 0.97 (0.93, 0.998) 0.0381 
Recurrent hospitalizations or death – Multistate 
model 
0.98 (0.95, 1.02) 0.3032 
 
The AG model with robust standard errors gave an estimated hazard ratio of 0.94 
(95% CI: 0.90 - 0.99), WLW model gave an estimated hazard ratio of 0.92 (95% CI: 0.86 
– 0.98), PWPa model gave the HR of 0.98 (95% CI: 0.95 – 1.02), and PWPb model gave 
the HR of 0.97 (95% CI: 0.93 – 0.998). The multi-state model accounting for different 
transition among the start of the study, sequence of death events after different number of 
hospitalization, gave the estimated HR of 0.98 (95% CI: 0.95 – 1.02). Overall, the treatment 
effect obtained from different recurrent event models are consistent, the magnitude of 
hazard ratios are broadly similar, with WLW model slightly overestimated treatment 
benefit, while PWPa, PWPb and multi-state model slightly underestimated treatment 
benefit compared to time to first hospitalization hazard ratio.  
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The results for Poisson and negative binomial model for hospitalization and death event 
rate within first year of the treatment are shown in Table 39.  
Table 39: Poisson and Negative Binomial Model Results for composite hospitalization and death event 
rate within first year of follow-up 
Model Rate ratio, 95% CI P-value 
Poisson model 0.946 (0.917, 0.977) 0.0006 
Poisson model with offset 0.945 (0.916, 0.976) 0.0005 
Negative binomial model 0.946 (0.898, 0.998) 0.0401 
 
The Poisson model with and without offset gave a similar rate ratio for the 
composite of recurrent hospitalizations and death of 0.95 (95% CI: 0.92 – 0.98) by 
comparing digoxin group with placebo. The negative binomial model yielded an estimated 
rate ratio of 0.95 (95% CI: 0.90 – 0.998, P =0.0401). Compared to the results obtained from 
the recurrent event model results, the rate ratios from event rate models are consistent with 
the recurrent event model when accounting for recurrent hospitalization events and death.  
The hierarchical endpoint Method 
The results of the hierarchical endpoints using generalized Gehan-Wilcoxon test 
are shown in the Table 40. Four hierarchical endpoints with death as the first priority 
components were evaluated, first two with two components, and another two with three 
components. In addition to the p-values generated from the generalized Gehan-Wilcoxon 
test, the win ratio defined as the total number of better outcomes divided by the total 
number of worse outcomes were also provided. 
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Table 40: Hierarchical Endpoints using generalized Gehan-Wilcoxon Test and Ratio Poisson and 
Negative Binomial Model Results for composite hospitalization and death event rate within first year 
of follow-up 
Hierarchical Endpoints Win ratio P-value 
Death, time to first hospitalization 1.03 0.2802 
Death, Number of hospitalizations 1.03 0.3070 
Death, time to first hospitalization, 
Number of hospitalizations 
1.03 0.2807 
Death, Number of hospitalizations, time to 
first hospitalization 
1.03 0.3052 
 
The results indicated that with all four hierarchical endpoints did not show 
statistically significant difference between two groups with the win ratio of 1.03 for all four 
endpoints. The reason can be explained by the small treatment effect size observed in 
improving survival and reducing hospitalization rate in long-term follow-up. In addition, 
the effect size in all-cause mortality was even lower than in effect size of all-cause 
hospitalizations. Based on the simulation studies, the power to detect treatment difference 
under this condition will be much lower compared to composite endpoint approach.   
6.3 Summary  
Out analysis of DIG trial data with long-term follow-up show that methods that 
take account of recurrent hospitalizations and death together can demonstrate a consistent 
and robust treatment effect benefit compared to what observed in the conventional time to 
first event analysis. As far as the hierarchical endpoints were concerned, all four 
hierarchical endpoints did not show much efficiency of detecting treatment benefit in the 
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hierarchical endpoints in the long-term follow-up, while it did show its utility as one way 
to assess treatment benefit in the DIG trial with one year follow-up. There were multiple 
reasons why the hierarchical endpoints did poorly compared to composite endpoint 
analysis in the long-term follow-up study. First, the estimated treatment effect in all-cause 
mortality is very minimal, HR=0.99 in the long-term follow-up data, and the all-cause 
hospitalization HR=0.95, while in the one year follow-up study with estimated HRs of 0.88 
and 0.86 for mortality and time to first hospitalization, respectively. Thus with hierarchical 
endpoint approach, with comparing survival time in the first priority, with HR=0.99, the 
chance to observe consistent better outcome in improving mortality in favoring digoxin is 
much reduced. Second, based on the simulation studies shown in the Chapter 5, when the 
effect size in the component compared in the first priority was smaller than what was in 
the component in the second priority, the power to detect overall treatment based on two 
components was lower compared to composite endpoint. Third, it might be true that the 
digoxin treatment did not improve the long-term benefit, but improves in the first year 
survival and delays hospitalization in the first year, or the all-cause mortality or all-cause 
hospitalization effect was diluted in the long-term follow-up because majority of deaths or 
hospitalizations were not associated with heart failure at all, or we need consider other 
covariates which confounded the treatment benefit in the long-term follow-up study. 
Thus, it is important to understand the performance of each endpoints prior to 
design the study, as the effect size ultimately determines the size of trial and follow-up 
duration. In the chronic diseases like heart failure, to account for treatment effect not only 
in mortality, but also the recurrent hospitalization events is even critical, as the 
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improvement of medical treatment in heart failure, the overall mortality rate has been 
dropping dramatically, however more non-fatal but clinical relevant events which impairs 
patients mobility and reduced their quality of life occurring during the long-term treatment.  
The results from recurrent event model including death and recurrent hospitalizations as 
the endpoint indicated its value to be considered a primary endpoint in the HF clinical trials. 
Although, the analysis might be a bit complicated compared to commonly used time to first 
event analysis, it shows overall benefit of treatment in improving mortality or reducing 
reoccurring hospitalization events. In our view, an analysis that takes account of all of the 
disease related cardiovascular events that occur as a result of a disease progression, rather 
than just the first event, gives a better description of the true burden of the disease and is 
also the real indicator for treatment effect.  
These analysis of DIG trial data show that digoxin did not have long-term effect in 
improving overall survival itself, but it reduced the risk of first admission to hospital, and 
decreases the incidence of repeated hospitalization events or death in the long-term follow-
up. We observe slight attenuation of the estimated treatment effects with recurrent event 
endpoints when taking the death as an additional event. This is to be expected given that 
the number of death events from both group are relatively small compared to 
hospitalization events and the treatment effect in time to death is not statistically significant 
with estimated hazard ratio of 0.88 (95% CI: 0.76 – 1.01, p=0.064). However, that all of 
the estimated rate ratio for the recurrent event endpoints of recurrent hospitalizations and 
death remain highly statistically significant.  
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In hierarchical endpoint analysis, the non-parametric approach based on 
generalized Gehan rank using pairwise comparison of composite endpoints in hierarchical 
manner did not show statistically significant treatment benefit with possible reasons 
described previously. However, this hierarchical endpoint approach is a reasonable 
approach to evaluate treatment benefit by reserving the first priority to compare treatment 
benefit in survival or most important and directly related efficacy outcome, followed with 
comparison of important but secondary clinical outcome which demonstrate treatment 
benefit while the first outcome is not applicable for pair-wise comparison. This has been 
shown in the simulation study as well, when the effect size in both mortality rate and 
hospitalization event rate is similar, the hierarchical endpoint will be as efficient as 
conventional composite endpoint or have higher power. However, if the effect in reducing 
mortality is not significant at all, or hazard ratio is close to 1, the efficiency of using 
hierarchical endpoint will dramatically be reduced because by comparing death in the first 
priority will overall reduce the estimate of treatment benefit.  
In conclusion, we evaluated some alternative endpoints for evaluating treatment 
benefit of digoxin in chronic heart failure patients in DIG trial with long-term follow-up 
data. The results based on recurrent event models showed the robust treatment benefit of 
digoxin in reducing recurrent hospitalization events or death compared to placebo; while 
the hierarchical endpoint approach did not show statistical significant treatment benefit 
result. Although the time to first event including composite endpoint of time to death or 
time to first hospitalization is more appealing for its simplicity and familiarity, we strongly 
feel in the future heart failure trials we should make the most of incorporating all 
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hospitalizations (not just for first) into the primary endpoint with regard to treatment benefit. 
Further evaluation of heart failure specific mortality or heart-failure related hospitalization 
events as more sensitive outcomes for digoxin treatment in long-term follow-up might be 
needed as the overall treatment benefit in survival and time to first hospitalization or 
recurrent event hazard ratios are not different from 1.   
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Chapter 7 Conclusion 
Endpoint selection is one of most important aspects in the clinical trial design, as it 
will have a great impact on determining the power of the study and the sample size 
requirement for the study. In the area of heart failure clinical trials, because of the small 
event rate in mortality, it will usually require large sample size and longer follow-up 
duration to accumulate sufficient events to have a reasonable power to detect treatment 
effect in mortality rate, thus a composite endpoint, time to death or time to first 
hospitalization, has been widely used as the primary endpoint to increase the event numbers 
during relatively shorter follow-up duration with much smaller sample size compared to 
the study with mortality as the primary endpoint. Despite the simplicity of time-to-first-
event analysis, this composite endpoint approach has a severe drawback: that is the waste 
of data collected during the clinical trials, ignores the multiple recurrent events that patients 
suffered and does not fully reflect the burden of heart failure in the current disease 
population. We evaluated the performance of multiple endpoints which include recurrent 
events in the simulation studies and the DIG trial data under two different type of designs 
with 1 year fixed follow-up and long-term follow-up with different follow-up durations for 
each patient.  
When the treatment effect in the mortality was similar to or better than the treatment 
effect in hospitalization rate, based on the simulation studies, the recurrent event models 
(AG model, WLW model, PWP model, and multi-state model) using extended Cox model 
provided consistent and higher power to detect treatment benefit reducing recurrent events 
of hospitalizations or deaths compared to composite endpoint using standard time-to-first-
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event Cox model. Thus, the inclusion of the recurrent hospitalization events and fatal 
events under this scenario increases the event numbers and help differentiate the treatment 
benefit from the placebo group. With the same reason, the Poisson model and negative 
binomial model also provided better power compared to composite endpoint analysis. 
However, if there are insufficient numbers of recurrent events available to include in the 
analysis, the benefit of recurrent event analysis might be lost as well as making the results 
harder to interpret. In addition, the above recurrent models and event rate models using 
multiple events from the same subject assume the events obtained from the same subject 
are independent or constant event over time or proportional hazards, thus the study data 
might not fully compliant with the required assumptions for those model, although the 
literature has indicated the above models provided relatively robust results when the 
assumptions were violated. Among those recurrent models, the multi-state model can be 
the best approach for recurrent event when the event type is different although the power 
is similar to AG and PWP models, for example in the HF clinical trials, the mortality and 
hospitalization event type are obviously distinctive in terms of the importance and severity. 
When using a multi-state model all patients start in the same state at the start of the trial. 
Patients then transition to other states when they suffer events. The states that patients 
transition to depend on the type of event they suffer. If the event patients suffer is death 
that means they can no longer participate in the trial they transition to absorbing state. For 
patients who transition to hospitalization event (non-absorbing state) they remain in that 
state until they suffer a further event. Patients then transition to another state. Again the 
states that patients transition to depend on the type of event they suffer. This modelling 
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process then continues for as long as patients are at risk of suffering events. Thus this model 
clearly differentiate different transition states among event type and event sequence.  
 The hierarchical endpoint approach under this condition provided an alternative 
reliable endpoint for testing treatment benefit in mortality or hospitalization event rate. 
Based on the simulation studies, when the treatment effect size in mortality is relatively 
larger than that in hospitalization event rate, with the hierarchical endpoint approach it had 
higher power compared to the results obtained from the composite endpoint or any 
individual endpoint. With hierarchical endpoint, it will compare the mortality data first, if 
death data is not applicable for comparing between pairs, the hospitalization information 
will be compared accordingly. However, when the effect size in death, the first hierarchical 
components in the hierarchical endpoints, is smaller than the second hierarchical 
components, this approach had lower power compared to composite endpoint, because by 
counting the death events first ultimately reduced the efficiency of separate the treatment 
effect with hierarchical endpoint, however, the approach provide more conservative and 
real assessment of treatment benefit while considering the importance of two different 
endpoints.   
However, in the DIG trial, the results from one year follow-up study dataset were 
different from what obtained from the long-term follow-up study. In the one year follow-
up dataset, digoxin showed statistically significant effect in both time to first event and 
recurrent event compared to placebo, and the HRs in time to first hospitalization and 
recurrent event were about 0.86, with p values <0.05, while in the long-term follow-up 
study dataset, the HRs in time to first hospitalization and recurrent hospitalization were 
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above 0.92 and for mortality the HR is close to 1. The reason might be explained by the 
insensitivity of all-cause mortality and all-cause hospitalization events between two groups 
while patients in long-term follow-up as many hospitalization events or deaths can be 
caused non-heart failure related disease burdens, which dilutes the treatment effect. To 
further look at the heart failure mortality and worsening heart failure hospitalization 
endpoints might distinguish the treatment benefit of digoxin in long-term heart failure 
treatment effect, or treating all other cause related death or hospitalizations as the 
competing risk in the models.  
A summary of the main findings are as follows: 
1. The false positive rate in all the test methods are pretty robust, with type I error rate 
about 5%, except for Poisson model under non-constant event rate situation. 
2. The power of detecting the treatment effect based on different endpoints increases 
when the sample size increases as expected. 
3. To include recurrent hospitalizations with death as the recurrent events and apply 
recurrent event models and event rate models, it increases the study power to detect 
the treatment effect compared to single endpoint or composite endpoint approaches.  
4. The hierarchical endpoints with mortality as the first hierarchy and the 
hospitalization data as the second hierarchy showed increased power to detect the 
treatment effect compared to composite endpoint (time to death or time to first 
hospitalization) when the treatment effect in improving mortality rate is larger than 
in reducing hospitalization event rate. When the effect size in hospitalization event 
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rate dominates, the power of detecting treatment benefit was less than that using 
composite endpoint approach. 
5. The hierarchical endpoint performs consistently well under constant hospitalization 
event rate assumptions or unequal hazard for first hospitalization and subsequent 
hospitalization events and the hospitalization events associated with HF mortality 
status.  
In chapter 3, we simulated close to real life scenario where the hospitalization events were 
associated with the patient survival status. The data from DIG trial suggested that for those 
deceased patient group, they usually associated with more frequent hospitalization events 
and earlier time to first hospitalization after entering the trial. In addition, the real data also 
indicated that the hazard of having the subsequent hospitalization is much higher than the 
hazard of having first event. Based on the additional simulation under the scenario where 
the hospitalization event rate might differ based on the survival status, in addition to the 
hazard of having first hospitalization event is also different from the hazard of having 
subsequent event, the hierarchical endpoint achieved higher power compared to composite 
endpoint when the effect in mortality rate is larger than or equal to that in the hospitalization 
rate. There are some limitations of the work in this presentation, such as the simulation did 
not consider the frailty of the hospitalization after occurring the first event and non-
proportional hazard in the time to event simulation, etc. These limitations provide 
opportunities for future research. In addition, in the real-life heart failure clinical trials, 
there are multiple predictive variables need to be considered for adjusting when performing 
Cox model or recurrent event models. For hierarchical endpoints, it might not be feasible 
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or straightforward to adjust the continuous independent predictive variables, but stratified 
analysis based on category might be a solution to adjust for those important covariates, 
such as ejection fraction or ACE medication, etc.  
In conclusion, the research work demonstrated if the true treatment effect in mortality is 
larger than or equal to that in hospitalization event rate, then a hierarchical endpoint may 
have higher power than the conventional composite endpoint without differentiating the 
mortality component and hospitalization component; if the true treatment effect in 
mortality is smaller than that in hospitalization, then a conventional composite endpoint 
has higher power compare to the hierarchical endpoint. However, the observed effect based 
on composite endpoint approach is weighed heavily by the treatment effect in 
hospitalization component without reflecting the contribution from the mortality 
component, which can lead to a wrong interpretation of the clinical results. Using 
hierarchical endpoint provides the clinicians the better and comprehensive understanding 
of the treatment effect while keeping the mortality information counted. Our research work 
on assessing the utility of hierarchical endpoint approach in HF in the fixed follow-up 
design is a new contribution to the area of HF clinical trial research, and the extension to 
the variable follow-up design with dynamic pair-wise comparison provides more flexibility 
for analyze hierarchical endpoint data in general design. This approach can be applied to 
oncology endpoints where the debate on whether to use overall survival or PFS as the 
primary endpoint has been going on for a long time, and other therapeutic areas as well. 
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